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SYNTHETIC METHODS AND BIOLOGICAL APPLICATIONS OF NITROGEN HETEROCYCLES TO 
COMPOUNDS OF BIOLOGICAL INTEREST 
Jarrid Ronnebaum 
April 23, 2019 
Thalidomide analogues were synthesized utilizing optimized click conditions from 
3-azidoglutarimide and an array of arylacetylenes or N-ethynyl/N-propargyl phthalimide 
derivatives. The intermediate, 3-azidoglutarimde, was pivotal and yielded a new and 
scalable synthesis. The reaction conditions utilized a copper sulfate/sodium ascorbate 
system in aqueous tetrahydrofuran to propagate the dipolar cycloaddition reactions 
between the azidoglutarimide and the alkynyl coupling partners. The first explored 
substrates were substituted arylalkynes to optimize the click reaction. Arylalkynes selected 
were to exhibit similar electron deficient rings to mimic phthalimide. Along with the 
synthesis of click thalidomide analogues, click analogue of the antiangiogenic and more 
potent teratogenic thalidomide analogue EM-12 was prepared.  
The isoindolinone group can act interchangeably with the N-phthaloyl nitrogen 
protecting group in amino acids. Amino acid intermediates using the N-isoindolinone 
group are used to make natural and unnatural a-amino acid derivatives using a two-carbon 
synthon. Selective benzylic oxidation was performed with the N-isoindolinone group being 
converted to the N-phthaloyl group (65–98%), which could be conveniently removed with 
hydrazine. For preparation of N-isoindolinone protected amino acids, an array of side 
v 
chains was installed on the isoindolinone-protected glycine equivalent. This was 
accomplished through selective deprotonation to demonstrate the utility of the N-protected 
isoindolinone synthon (51–93%). Selective oxidation is employed on the benzylic N-
isoinodolinone with OxoneÒ/KBr and successfully converted the N-isoindolinone group to 
the N-phthaloyl group in simple substrates, but substrates bearing unsaturated or electron-
rich side chains respond poorly to the oxidation.  
The alkoxylation of chiral N-phenethyl hydroxyisoindolinones were synthesized 
with diethylaminosulfur trifluoride and an array of primary and secondary alcohols. The 
mechanism by which synthesis alkoxyisoindolinones are synthesized is through generation 
of an N-acyliminium ion to allow alkoxylation. The alkoxylated product exhibits a 
diastereomeric ratio influenced by the chiral N-phenethyl with a favored diastereomer. The 
stereochemistry and mixture of diastereomers were observed through this reaction. 
vi 
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             PART A. SYNTHESIS OF “CLICK” 
                   THALIDOMIDE ANALOGES
2 
Introduction 
Thalidomide, developed initially as a sedative, is responsible for one of the most 
tragic histories in the era of drug discovery, but has since been reassessed for new purposes 
that have been proven beneficial. Thalidomide was synthesized and sold as “Contergan” 
by Chemie Grunenthal, a West German Pharmaceutical company, and patented in 19561. 
Thalidomide was claimed to possess sedative properties and was prescribed to treat 
morning sickness for pregnant women in 46 countries2. Lenz3 and McBride4 independently 
reported in the early 60’s that thalidomide was associated with pregnancies resulting in 
children being born with major congenital abnormalities3-6. The severity of the birth defects 
recorded ranges from internal organs being deformed, cleft lip, to amelia or phocomelia. 
Amelia being the total lack of a limb and phocomelia being that the hand or foot attached 
near trunk. More than 12,000 children were affected by the teratogenic effects of 
thalidomide and therefore the drug was removed from the United Kingdom in late 1961. A 
short time after thalidomide was completely removed from the majority of the worlds 
markets by 1962. During the time of thalidomide distribution, an increased rate of 
miscarriages was reported as well7. Though thalidomide was shown to be an incredibly 
potent embryotoxin, it was still being used in some countries where it portrayed significant 
efficacy.  
Figure 1. Thalidomide chemical structure. 
Thalidomide, shortly after its removal form the market as a drug, was reported by 
Sheskin in 19658 to be very effective in treating erythema nodosum leprosum (ENL), the 
1 
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skin lesions associated with leprosy.s The World Health Organization confirmed its 
beneficial effect in thousands of men for ENL after the initial report by Sheskin. In 1980, 
Sheskin reported the efficiency of thalidomide in ENL as over 99% effective in 4522 
patients9. Typically, positive responses were observed within a 24-48 hour time period 
including the improvement of symptoms9 such as: lesions, fever, and night sweats.  Despite 
thalidomides’ positive impact on ENL, side effects occurred, ranging from headaches to 
polyneuritis. Following conclusion of treatment, the numbness in patients’ extremities 
tended to subside. In patients with ENL, Tumor Necrosis Factor a (TNF-a) and Interferon 
g (IFN-g)  were elevated, but upon thalidomide administration levels of both cytokines were 
decreased10. TNF-α is a molecule that plays a crucial role in inflammation, making its 
inhibition particularly useful for inflammatory diseases. This observation led to the interest 
in thalidomide for its immunomodular effects. 
Thalidomide through the 80’s and into the early 90’s underwent very little change in its 
structure while being clinically evaluated in ENL and multiple other skin diseases. Due to 
its ban in many countries, only small sample cases were conducted to show thalidomide 
aided in the ailments of Behcet’s disease11, rheumatoid arthritis12, systemic lupus 
erythematosus13, and graft versus host disease.14,15 Considering the severity and unknown 
mode of action for thalidomide’s teratogenicity, the use of this drug in many autoimmune 
diseases was only considered once outside of clinical trials, with the only exception being 
ENL. Thalidomide’s structure was first altered in response to the discovery of its ability to 
inhibit TNF-α. Alterations of the glutarimide moiety lead to the first derivatives of 
thalidomide’s structure and were synthesized to increase its inhibitory effects on TNF-
α.16,17   
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Three decades have passed since one of the initial uses of thalidomide for antitumor 
properties was reported in 1965 by Olsen et al18 by using thalidomide on individuals with 
a range of advanced cancers. In 1999, Singhal et al19 reported the reexamination of 
thalidomide for its antitumor properties in refractory multiple myeloma. While multiple 
myeloma accounts for approximately 10 percent of hematological cancers, it is incurable 
with conventional chemotherapy. Multiple myeloma often sees a relapse of the cancer after 
high-doses of chemotherapy and angiogenesis can accelerate tumor progression of 
hematological cancers. Thalidomide and its anti-angiogenic properties have been effective 
in slowing tumor progression in the treatment of refractory multiple myeloma.  In the 1999 
study, thalidomide was used for a small group of refractory multiple myeloma patients and 
10 percent of patients showed complete remission and a third was observed to have at least 
a 25% reduced paraprotein level. Since the first in vivo efficacy of thalidomide in refractory 
multiple myeloma, thalidomide has been shown to be most effective when given in a 
combination of thalidomide with another anticancer drug. In most cases, the combination 
of drugs is better than using solely thalidomide or using solely the combinatory drug.20 A 
specific case included the use of thalidomide with low doses of dexamethasone, in which 
it was used to treat advanced multiple myeloma and proved to be more potent than either 
of them individually. Using the combination drug approach, the technique of using 
thalidomide with melphalan or cyclophosphamide has also shown to be potent combination 
therapies to obtain remission of multiple myeloma.  
In 2010, Ito and Ando21 used a novel thalidomide beads approach to discover that 
thalidomide binds selectively through the glutarimide ring to the N-terminus of the protein 
cereblon (CRBN). CRBN is a protein of the ubiquitin E3 cullin 4-RING ligase (CRL4) 
5 
complex containing the proteins; damaged DNA-binding protein 1 (DDB1), cullin 4 
protein (Cul4), and CRBN to form the complex CUL4ACRBN. Ubiquitin complexes tag 
proteins to be decomposed by a proteasome, effectively downregulating a specific protein. 
The immunomodulatory drugs (IMiDs), consisting of thalidomide, lenalidomide, and 
pomalidamide, have been shown to bind CRBN and aid in the selective ubiquitination of 
proteins in the CUL4ACRBN complex. The CUL4ACRBN   is useful in maintaining metabolic 
homeostasis through degradation of glutamine synthetase in hepatic cells, where glutamine 
is at high concentration.22 The binding of thalidomide acts as an allosteric regulator to 
cereblon and downregulates proteins that control the expression of growth factors 
responsible for teratogenic properties.21 Though teratogenic properties exist, there is a 
benefit of both thalidomide and lenalidomide in treating multiple myeloma through the 
binding and the downregulation of Ikaros family zinc finger protein (IKZF) 1 and 
IKZF3.23,24 In contrast, when bound in the CRBN pocket lenalidomide also downregulates 
casein kinase 1A1 (CK1a) post translationally.25 This provides a structural basis to make 
new drug targets that possess the glutarimide moiety while utilizing the CRL4CRBN 
ubiquitin complex in an opportunistic manner. This technique gives insight in to the 
potential mode of action in which thalidomide acts as an anticancer agent.  
Thalidomide most recently has been being explored for targeted protein knockdown. 
Chemicals capable of inducing protein degradation are seen as a potential drug candidate 
due to their ability to induce a chemical knockdown of a targeted protein. Of one specific 
chemically induced knockdown, thalidomide is used with a paired chimeric molecule used 
as PROTACs (Proteolysis-Targeting Chimeras). Thalidomide is currently being 
investigated to act as one portion of a PROTAC to invoke an E3 ubiquitin ligase.26 This is 
6 
completed through thalidomide acting as a ligand of the cereblon protein to facilitate use 
of the E3 ubiquitin complex in targeted protein ubiquitination. PROTACs containing the 
thalidomide ligand and another inhibitory ligand is proximate to the ubiquitin complex and 
the new protein to induce poly-ubiquitylation. This poly-ubiquitylation has a down 
regulation of a new protein through the chimeric ligand and was first reported in down 
regulating bromodomain-containing protein 4, BRD4 (Figure 2). Since the applicability of 
PROTACs, 2, being used for down regulation of BRD4, a class of PROTACs have been 
used on a range of differing proteins.  
Figure 2. PROTAC bearing a thalidomide to downregulate BRD4. 
The metabolic pathway by which thalidomide possesses both antiangiogenic and 
teratogenic nature has gone through many hypothetical metabolic pathways. While 
thalidomide has been shown to inhibit TNF-a synthesis, there has been no link to correlate 
the inhibition of TNF-a with its teratogenic activity. On the other hand, thalidomide’s 
antiangiogenic activity shows correlation toward its ability to act as a teratogen 
independently of its immunosuppressant/immunomodulatory activity. One of the first 
hypothesized mechanisms of action of thalidomide being a teratogen was proposed by 
Jönsson in 1972.27 Jönsson proposed that the teratogenic action of thalidomide was through 
the intercalation in DNA through a stacked complex that allows for a flat phthalimide ring 
2 
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to form with the deoxyguanosine. It was hypothesized that thalidomide would bind to 
guanine-rich sites, however linking this to teratogenicity was a hard pathway to justify due 
to the lack of specificity of intercalation on specific gene expressing regions. Other 
mechanisms have been explored to explain the teratogenicity nature of thalidomide 
including: reactive oxidative stress-inducing cell death, chondrogenesis, and nerve 
toxicity/neural crest loss.28-33 Through the years thalidomide’s beneficial pharmacological 
effects included anti-tumor promoting activity, anti-angiogenic activity, anti-viral activity, 
and hypoglycemic activity. Regulation of certain cytokines; TNF-a, interleukins 2, 4, 5, 6, 
10, and 12, and interferon-g, affect the population of T-cells and the hypothesis was that 
this stemmed from the regulation of TNF-a.34-35 While all of these have been observed, 
finding a direct mode of action for any of these has never been completely elucidated, but 
has been a major reason for synthesizing derivatives of thalidomide as a means of 
elucidating a specific mechanism.  
Thalidomide is a highly crystalline compound and is relatively insoluble in most 
organic solvents. While being mostly soluble in highly polar organic solvents; 
dimethylsulfoxide, dimethylformamide, and pyridine, thalidomide has poor aqueous 
solubility and has instability under physiological pH. The instability stems from the 
chemical transformations that do occur in the form of racemization at the enolizable 3¢ 
position on the glutarimide ring and hydrolysis of thalidomide. The general hydrolytic 
cascade demonstrates the breakdown of thalidomide under biological pH and begins with 
either the opening of the phthaloyl or glutarimide ring (Scheme 1). Looking at the left-
hand side of the cascade, the partial hydrolysis of the phthaloyl ring yields first a 
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o-phthalic acid 6 and aminoglutarimide 7. Glutarimide 7 undergoes hydrolysis to yield 
either glutamine 12 or isoglutamine 11 that both can suffer hydrolytic cleavage to yield 
glutamic acid 14. Though phthalimide hydrolysis is plausible, complete hydrolysis of the 
glutarimide ring is equally plausible to yield either N-phthaloyl glutamine 5 or N-phthaloyl 
isoglutamine 4 and can be seen on the right-hand side of cascade. Hydrolytic cleavage of 
4/5 yields N-phthaloyl glutamic acid 9 or hydrolysis of the phthaloyl to synthesize the 
carboxybenzamidic acid derivatives 8/10. Complete hydrolysis of 8 or 10 would yield both 
11 and 12, respectively. A mixture of the opening of the glutarimide ring and phthaloyl 
ring is plausible as well and can be seen as intermediates deviating from the cascades 
aforementioned, but all processes of the hydrolytic breakdown result in 6 and 14.  
Although thalidomide itself initially was notorious as a potent embryotoxin, it has 
since been highly beneficial to the medicinal community through utilization of its 
derivatives. Thalidomide has a unique numbering by which derivatives are denoted through 
giving first priority numbering to the phthalimide ring followed by the glutarimide ring 
denoted with a prime numbering (Figure 3). The first derivative of thalidomide was 
accomplished through removing a benzylic carbonyl, also known as EM-12 15 (Figure 
4).36 EM-12 has been observed to be a more potent teratogen than thalidomide in the New 
Figure 3. Thalidomide numbering. 
1
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Figure 4. Structural conformation of EM-12. 
Zealand white rabbit. Since a multitude of thalidomide analogues have been synthesized in 
an attempt to gain an understanding of its teratogenic properties and mechanism of action. 
An early set of thalidomide-based compounds were made and tested by Jönsson in 1972 to 
attempt to discern what chemical properties are necessary for teratogenicity.27 Of the 
compounds tested by Jönsson (Figure 5), teratogenic studies of the compounds were 
conducted on rabbits, chickens, and Wistar rats and organized according to malformation 
Figure 5. Thalidomide derivative synthesized by Jönsson to determine chemical structure 
requirements for thalidomide. 
and fetal resorption. This study was able to shine light on species dependent teratogenicity 
which was seen in the 4¢-phthalimido analogue 16 by causing limb malformations in the 










benzyl substitution in 4-nitrothalidomide 17 and the reduction partner 4-aminothalidomide 
18 both caused malformations and fetal resorption in rabbit. Hydroxylated thalidomide 
analogues on the benzene ring in both 4- and 5-Hydroxythalidomide 19 and 20 both caused 
limb malformations in the chick embryo. Non-planar phthalimide derivatives, cycloalkyl- 
or tetrahydrophthalimide 22 and 21 respectfully, were both found to be non-teratogenic. 
To further understand the role of planarity on the “phthalimide” side, a group from the 
University of Bonn made partial planar analogues that lacked conjugation similar to 
compounds proposed by Jonsson (Figure 6).37 The partially planar alkyl derivatives 23 and 
24 proved not to be teratogenic will the dithia compound 25 showed to be teratogenic. The 
attempts from the group atBonn to prove or disprove the intercalation theory based upon 
having planar molecules was neither solidified or disproved.  
Figure 6. Thalidomide derivates that lack conjugation and planarity within the 
phthalimide ring. 
Researchers from Grunenthal Research Center evaluated thalidomide derivatives 
for teratogenic activity.38 The compounds, EM-12, EM-136 26, EM-255 27, EM-8 28, EM-
87 29, were tested using the New Zealand white rabbit for teratogenic studies. Of all the 
compounds tested, 15 was found to be more teratogenic than thalidomide and the most 
teratogenic overall. While 15 was the most teratogenic, 26 was comparable to thalidomide 
in teratogenicity followed by 27, 28, and 29 respectively (Figure 7.). While 15 was 
included in the study with New Zealand white rabbits, EM-12 was already a known 
teratogen when tested in non-human primate species. Teratogenicity studies were 
23 24 25 
12 
complicated in nature due to the species-dependent nature of thalidomide.39-42 While some 
animals exposed to thalidomide, like the New Zealand White (NZW) rabbits and Wistar 
Rats, parented offspring with phocomelia/amelia, certain species such as non-NZW rabbits 
resorb malformed fetus in utero. As well, rodents tend to show a varying range of results 
and being mouse strain specific for teratogenic results.43,44 With thalidomide having 
species dependent teratogenic properties, studies were conducted on a range of non-human 
primates as the morphology of non-human primates is most analogous to humans. Many  
Figure 7. Chemie researchers synthesizing derivatives to determine teratogenic 
requisites. 
non-human primates have been tested with thalidomide throughout history with a vast 
majority displaying phocomelia/amelia in offspring. Difficulties arise while studying 
rabbits and non-human primates including the fact that they typically produce small litter 
and gestation can take a long time, such as the case of non-human primates. In rodents as 
well as rabbits and non-human primates, the embryo cultures exposed to thalidomide does 
not provide a way to monitor limb formation progress. Zebrafish and chick embryo cultures 
have provided insight and adequate models to examine the limb formation progress. 45,46 
26 (EM-136) 27 (EM-255) 
28 (EM-8) 29 (EM-87) 
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While individual thalidomide derivatives were seen to be teratogenic, the efficacy 
of thalidomide’s treatment for symptoms of ENL were noted to coincide with the decrease 
of elevated levels of TNF-a in patients with ENL. This observance led to the synthesis of 
thalidomide derivatives targeted for the downregulation of TNF-a to aid in the treatment 
of symptoms for ENL. TNF-a is a member of the TNF family that consists of cell surface 
and secreted molecules that mediate host defense and immune regulation. TNF-a is mainly 
produced by T cells and macrophages in response to multiple stimuli that relate to pro-
inflammatory properties. Several novel polyhalogenated thalidomide derivatives 30-32 
were reported with the goal of synthesizing thalidomide derivatives with improved TNF-a 
suppression (Figure 7).47 Of the polyhalogenated derivatives, tetrafluorothaldiomide 30 
was reported to show suppression of TNF-a and was observed to be more potent than thal- 
Figure 7. Polyhalogenated thalidomide derivatives. 
idomide under similar circumstances. It was also able to reach IC values within the single 
digits compared to that of thalidomide which was over 200 nM. Also, a number of 
thionothalidomide derivatives 33-35 have been synthesized by replacing one of the four 
carbonyls with a sulfur (Figure 8).48 These derivatives were synthesized using Lawesson’s 
reagent under different reaction conditions to yield either dithiothalidomide 33/35 in 
pyridine, or trithiothalidomide 34 in a mixture of morpholine and toluene. 
30 31 32 
14 
Figure 8. Potential thionolthalidomide derivatives from treatment of thalidomide with 
Lawesson’s reagent. 
Derivatives of thalidomide specifically tailored towards downregulation of TNF-a 
were being explored during the early 1990’s by He and co-workers in development of a 
therapeutic for graft vs. host disease.49 Derivatives synthesized by He and co-workers for  
Scheme 2. Synthetic approach of thalidomide derivatives by He and coworkers. 
Figure 9. Thalidomide derivatives synthesized by He and coworkers. 
33 34 35 
36 37 38 
39 40 41 
42 43 44 
45 46 
15 
TNF-a suppression consisted of minor substitutions to the phthaloyl ring while keeping 
the glutarimide ring intact (Scheme 2). The phthaloyl derivatives entailed the addition of 
functional groups; nitro, amino and hydroxyl, or adding a nitrogen within the benzyl ring. 
The thalidomide derivatives 39-46 were synthesized easily from 3-aminoglutarimide 36 
and the partner substituted phthalic anhydride 37. Some of the compounds (Figure 9) were 
shown to be promising in the TNF-a suppression of human peripheral blood lymphocytes, 
while also being tested for proficiency in graft vs. host disease in animal models.  
Shortly after the reporting of He and co-worker’s compounds, Kaplan and Sampaio 
patented thalidomide and analogues in 1995 for the treatment of abnormal TNF-a levels.50
Tested within their patent were hydrolytic breakdown by-products of thalidomide and EM-
12. In looking for potent TNF-a inhibitors, Celgene published a set of molecules that were
inspired by the hydrolytic breakdown of thalidomide to determine whether thalidomide or 
a natural metabolite is more potent in inhibiting TNF-a.51,52 One such pathway for 
hydrolytic breakdown of thalidomide under biological pH occurs through the hydrolytic 
opening of the glutarimide ring. The hydrolysis of the glutarimide ring was the basis for 
design of a class of molecules that were seen to inhibit not only TNF-a but more 
specifically the phosphodiesterase (PDE) 4 47 (Figure 10).53 PDE4 is a major enzyme that 




is responsible for a majority of TNF-a production in monocytes. This garnered much 
attention and led to multiple derivatives including a potent TNF-a inhibitor that contained 
a tetrafluorinated phthaloyl ring 48. Research into utilizing metabolite inspired thalidomide 
derivatives has led to the discovery of the commercial drug Apremalist, 49 a PDE4 
inhibitor used to treat psoriasis (Figure 11).54 
Figure 11. Apremalist chemical structure based off thalidomide derived PDE4 inhibitors. 
In the quest for PDE4 inhibitors, Celgene also reported one of the most notable 
derivatives of thalidomide; lenalidomide, 50 (Figure 12), an analogue of thalidomide.55 
Being structurally similar to 15, it is an anticancer drug for multiple myeloma (MM) and 
myelodysplastic syndrome (MDS) that has brought thalidomide and its analogues officially 
back to the market in 1998. Initial studies of 50 were performed to synthesize TNF-a 
inhibitors that did contain the teratogenic nature of thalidomide. As noted from the study 
in 1999 by Singhal et al.19, a study to show the efficacy of thalidomide at reducing tumor 
growth specifically, multiple myeloma. Lenalidomide was also tested for its ability to 
reduce tumor growth and showed more potency and effectiveness at treating 
myelodysplastic syndrome. Due to the teratogenic nature of thalidomide, testing the 
teratogenicity of 50 was tested with pregnant New Zealand white rabbits.56 Dosing of te 
animals ranged from 0-20mg/kg/day during the 7-19 day gestation period and no fetal 
malformations were noted at this dosing, and not until approaching toxic dosing levels did 
49 
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fetal malformations become observed. 50 has also been extensively studied in similar 
biological studies that thalidomide is active in TNF-a inhibition,57 anti-cancer properties, 
and binding within CRBN.25  
Figure 12. Chemical structure of lenalidomide. 
Thalidomide possesses an enolizable a-proton on the glutarimide ring off of carbon 
3¢ and undergoes racemization in vitro. The racemization properties of thalidomide 
complicate the understanding as to whether or not a single enantiomer is a more potent 
teratogen. Configurationally stable analogues of thalidomide have been synthesized and 
studied to understand if a specific enantiomer has the higher biological activity. 
Substitution of the proton with deuterium on the enantiomeric carbon is a small change but 
generates a configurationally stable enantiomer, 51 and 54. Other substitutions of the 
proton on the 3¢ position include fluorine 52 and 55 and methyl substitutions 53 and 56 
which can be resolved to yield enantiomerically pure analogues of thalidomide that do not 
contain an easily racemizable carbon position (Figure 13).58-61 While the latter have been 
synthesized as enantiomerically pure analogues, a racemic mixture of a dimethyl and 




Figure 13. Thalidomide derivatives bearing 3¢ substitution to reduce racemization. 
Derivatives bearing substitution off of the benzyl ring of the phthalimide portion, 
was shown to be successful by lenalidomide and substitution off of the phthalimide has 
been greatly explored for anticancer and angiogenic activity. Multiple examples were 
reported by a group in the Molecular Pharmacology Section of the NCI in collaboration 
with University of Leipzeig group. The compounds were linked to the amino acid 
derivatives off of the free nitrogen on the glutarimide ring through an ester linkage, 59-62 
(Figure 14).62 The amino acid-derived thalidomide analogues and a hydroxymethylated 
glutarimide thalidomide analogue proved to be potent inhibitors in the rat aortic ring assay. 
The most potent were the N-hydroxymethylatedthalidomide 59 and the pheylalanine ester 
derivative 60 were shown to be significantly more potent. Under hydrolytic conditions, 59 
would convert to thalidomide the usual mechanism of action was exhibited.  
51 52 53 
54 55 56 
57 58 
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Figure 14. N-substituted thalidomide derivatives. 
When evaluating the derivatives of thalidomide that have been synthesized for 
thalidomide, the substitution on thalidomide or the replacement of atoms in this molecule 
has been highly explored. A few core structural features seem to be apparent: an intact 
phthalimide or phthalimidine ring connected to a glutarimide ring of the C-3¢ position and 
the glutarimide containing both carbonyls with the nitrogen bearing a proton. Extensive 
reviews of many classes of derivatives synthesis have been completed.63 While many 
derivatives have been studied, one area that has not been completely explored is a linker 
between the phthalimide and glutarimide rings. The linker between the two would resemble 
that of a “fleximer” concept which has been proven useful in nucleoside chemistry. 
Whereby an additional heteroatom inserted between a nucleoside sugar and heterocycle 
base has been shown to be beneficial.64 
One such way that a “fleximer” has shown to be beneficial is the 1,2,3-triazole ring 
in sugar chemistry. The 1,2,3-triazole ring has been reported extensively and is synthesized 
through a copper catalyzed reaction with an azide paired with an alkyne. The triazole ring 




a more potent compound. The ease of synthesis of the triazole has been used for 
thalidomide analogues where substitution is seen off of the glutarimide ring nitrogen and 
off of the benzylic positions of the phthalimide ring. Compounds containing a triazole 
component of the phthalimide ring have been explored in the use of PROTAC’s. 
PROTAC’s with triazole derivatives has been prepared where both the substitution on the 
phthalimide contributes as either the azide or alkyne as a partner for the click reaction.65 A 
PROTAC, 63 bearing the triazole have shown biological efficacy in the downregulation of 
sirtuin protein (2) that results in the hyperacetylation of the microtubule framework 
(Figure 15). Although the compounds contain a triazole either on the glutarimide or 
phthalimide, a triazole acting as a linker between a phthalimide and glutarimide could yield 
interesting biological properties.  
Figure 15. PROTAC developed to target the downregulation of Sirt2. 
Herein we describe the synthesis of a class of “click” thalidomide analogues that 
possess a triazole linker between the glutarimide and the phthalimide/phthalimide mimic. 
Synthesis of 3-azido glutarimide is described as a partner for all click thalidomide 
analogues described herein. Utilizing commercially-available alkynes with a novel 3-
azidoglutarimide reacting partner, a base reaction condition was developed with a simple 
adjustment of conditions. Under optimized conditions, preparation of triazole spacer click 
63 
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analogues of thalidomide and EM-12 were demonstrated utilizing their respective N-
alkynyl phthaloyl/isoindolinone. Homologues containing a triazole-methylene spacer were 
synthesized as well to determine whether the size of space contributes to overall reactivity. 
As well, a range of electron deficient fluorinated phenyl acetylene rings were used to act 
as phthaloyl mimics when paired with the azido-glutarimide.66 
Results and Discussions 
The route to the synthesis of 1,2,3-triazole derived thalidomide analogues utilizes 
a 3-azido-substituted glutarimide 66. Commercially available glutarimide undergoes 
bromination alpha to the carbonyl when glutarimide 64 is reacted with molecular bromine 
in a sealed vessel with chloroform at 100 °C in a Kugelröhr oven. The bromoglutarimide 
65 was subjected immediately to an azidation reaction after removal of the chloroform due 
to the sensitivity of 65, in which decomposition is observable by crude mass calculations 
through purification with column chromatography. Azidation of the crude a-bromo lactam 
65 is accomplished by adding an excess of sodium azide and allowing the reaction to stir 
as a purple-blue reaction in acetone. Upon purification, by gravity column 
chromatography, a mixture of desired 3-azido glutarimide 66 and unreacted 65 was 
observed and subsequently the mixture of both delete is subjected to azidation again 
through the aforementioned conditions. Undergoing an additional azidation reaction, 
purification of 66 by gravity column chromatography gives an off-white crystalline product 
with no starting material present (53%) (Scheme 3).  
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Scheme 3. Preparation of azidoglutarimide. Reagents/Conditions: (a) Br2/CHCl3/ 100 
°C/45min; (b) NaN3/Me2CO/rt/16 h (53% from glutarimide). 
Azido glutarimide 66 is theoretically able to undergo a copper catalyzed azido-
alkyne “click” cycloaddition reaction with an alkyne. The reactivity of 66 was attempted 
utilizing TMS protected N-alkynyl phthalyl synthesized by a method provided by Davies 
et al67 A range of conditions were explored utilizing differing solvent condition and 
determining the correct copper source such as; acetone, DMSO:H2O, THF:H2O, and 
copper (I)iodide, and copper (II) sulfate. The reaction conditions that generated detectable 
product were copper sulfate (.1 molecular ratio) with sodium ascorbate (.15 molecular 
ratio) in an aqueous THF (9:1 H2O) solvent system. Utilizing these conditions, 
phenylacetylene was used as a reactant along with 66 to demonstrate the reactions 
applicability with aryl acetylenes.  Utilizing CuSO4 (0.1 equiv.) and sodium ascorbate (0.15 
equiv.) in aqueous THF as optimized conditions, 66 was reacted with phenylacetylene 67 
to undergo a click reaction to synthesize pure white crystalline product in modest yield 
(78%) upon purification by gravity column chromatography. Upon optimizing the reaction 
conditions with 67, a range of fluorinated arylacetylenes 68-71 were paired with 66 after 
taking into consideration the potency of fluorinated analogues of thalidomide in literature. 
Fluorinated arylacetylenes also contain an electron deficient ring similar to the electronics 
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were reacted under optimized conditions to yield white crystalline products after 
purification by column chromatography in yields ranging from 76-98% (Table 1). 
Table 1. Cycloaddition products of arylacetylenes with 3-azidoglutarimde. 














Reagents/conditions: (a) CuSO4/sodium ascorbate/THF/H2O/rt/16 h. 
In order to synthesize triazole linker thalidomide analogues, N-ethynyl and N-
propargyl reacting pairs for thalidomide analogues were prepared (Scheme 4). The N-
a.
.66 67-71 72-76 
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propargyl phthalimide 78 was prepared through a base-generated nitrogen anion with 
cesium carbonate in acetonitrile. The base generated anion was reacted in situ with the 
electrophile, propargyl bromide, and gave 78 as an off-white solid in good yield (69%).  
Scheme 4. Synthesis of N-propargyl isoindolinone. Reagents/conditions: (a) propargyl 
bromide/Cs2CO3/MeCN/80 °C/2 h (69%) 
While isoindolinone 79 is commercially available, a one-pot reduction of 
phthalimide 77 was performed using tin under Lewis acid conditions. Stirring 77 under 
reflux with tin in acetic acid and concentrated hydrochloric acid yielded isoindolinone 79 
in a yield (39%), similar to that previously reported.  Propargylation of isoindolinone was 
accomplished by the same base-generated nitrogen anion with cesium carbonate and 
propargyl bromide as the electrophile to yield N-propargyl isoindolinone 80 as a white 
solid in good yield (65%) (Scheme 5).  
Scheme 5. Synthesis of N-propargyl isoindolinone. Reagents/conditions: (a)	propargyl 
bromide/Cs2CO3/MeCN/80 °C/2 h (65%) 
The homomethylene click thalidomide analogue was synthesized using 78/80 and 
66. The reaction conditions utilized were the same as those previously described, with




77 79 80 
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at room temperature for 16 hours. The reaction of azidoglutarimide with N-propargyl 
phthalimide/isoindolinone yielded white crystalline product in 67 and 61% yields 
respectively (Table 2). 
Table 2. Cycloaddition products of N-propargyl phthalimide/isoindolinone with 3-
azidoglutarimde 





Reagents/conditions: (a) CuSO4/sodium ascorbate/THF/H2O/rt/16 h. 
The N-ethynyl phthalimide/isoindolinone 84/86 are synthesized to give 
thalidomide/EM-12 analogue bearing only the triazole linker between the glutarimide and 
phthalimide/ isoindolinone (Scheme 6). The synthesis of the 84 utilized TMS-acetylene 
under conditions described by Davies.66 In performing this method, phthalimide is stirred 
with copper acetate, pyridine, and ethynyltrimethylsilane under an oxygen atmosphere and 
afforded intermediate, 2-((trimethylsilyl)ethynyl)isoindoline-1,3-dione 83 as a crystalline 
solid. The intermediate 83 is desilylated with TBAF in acetic acid and provided a 
moderately unstable 2-ethynylisoindoline-1,3-dione 84 in a moderate yield (55% over two 
steps). Ethynylation of the isoindolinone was performed using copper acetate as a catalyst 
a.
78/80 66 81/82 
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with sodium carbonate and pyridine present in toluene under an oxygen atmosphere. The 
reaction which proceeded over an hour, while stirring at 70 ºC, turned from a blue to a 
bright green reaction in which TMS-acetylene was added and the reaction was stirred for 
4 hours resulting in a bright green to a black suspension. After filtering the black suspension 
with Celite®, purification of 2-((trimethylsilyl)ethynyl)isoindolin-1-one 85 was done by 
flash column chromatography to give fluffy white solid. The N-isoindolinone proton is less 
Scheme 6. Synthesis of N-ethynyl phthalimide (top) and isoindolinone (bottom). 
Reagents/Conditions: (a) ethynyltrimethylsilane/Cu(OAc)2/O2/pyridine/Na2CO3/70 °C/16 
h (83, 59%; 85, 22%); (b) TBAF/THF/AcOH/rt/16 h (84, 94%); (c) TBAF/THF/rt/16 h 
(85, 92%) 
acidic than that of the N-phthalimide proton and is giving a less reactive starting material 
for ethynylation under the conditions proposed by Davies, but product is still observed in 
a lower yield compared to the phthalimide. While the ethynylation of isoindolinone is not 
as facile, generating the desilylated product 86 was easily accomplished using TBAF in 
THF to give a crystalline solid after purification by column chromatography (20% over 
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Freshly prepared 84 and 86, due to relative instability, were immediately used in 
the cycloaddition reaction with azido glutarimide (Table 3). The reaction conditions for 
cycloaddition were the same as those previously describeed, with copper sulfate (0.10 
molar equiv) and sodium ascorbate(0.15 molar equiv) in aqueous THF and stirring at room 
temperature for 16 hours. The reaction of 66 with 84 yielded “click” thalidomide as white  
Table 3. Cycloaddition products of N-ethynyl phthalimide/isoindolinone with 3-
azidoglutarimde 







Reagents/conditions: (a) CuSO4/sodium ascorbate/THF/H2O/rt/16 h.  
crystalline product at good yield, 83% respectively. As well, reaction of 86 was 
immediately reacted with 66 under the same reaction conditions. The product utilizing the 
N-ethynyl isoindolinone afforded the “click” EM-12 analogue 88 as white crystalline solid 
at a moderate yield of 78%. While both were purified by column chromatography, neither 
compound is very soluble in most organic solvents.  
a.
66 84/86 87/88 
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While exploring the synthesis of the N-ethynyl isoindolinone for the “click” EM-
12 analogue, alternative pathways were explored before utilizing the Davies61 method for 
ethynylation. Initial attempts to synthesize N-ethynyl isoindolinone involved which 
utilized the TMS protected N-ethynyl phthalimide and synthesizing the TMS protected N-
ethynyl isoindolinone through reduction of a carbonyl, thiolation of the alcohol, and 
subsequent desulfurization to overall reduce a carbonyl to a methylene (Scheme 7). 
Reduction of the single carbonyl was attempted with sodium borohydride in methanol but 
was unsuccessful in synthesizing the hydroxylactam, and the reaction by TLC showed 
complete decomposition. Another reduction utilizing an aluminum amalgam was 
successful in generating the TMS protected N-ethynyl hydroxylactam. The TMS protected 
N-ethynyl phthalimide was stirred in a reaction of THF:H2O (9:1) while strips of 
aluminum, washed in diethyl ether then dipped into a solution of HgCl2, were added. The 
reaction proceeded for 30 minutes by which all starting material was consumed to afford 
the TMS protected N-ethynyl hydroxylactam 90. Lactam 90 was subjected to 
phenylthiation by using thiophenol in slight excess (1.2 equiv) with a crystal of p-
toluenesulfonic acid. The reaction mixture was stirred in dichloromethane (2 hours) while 
being monitored by TLC, and after purification contained no detectable TMS or alkynyl 
protons in 1H NMR.  
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Scheme 7. Proposed synthesis of N-ethynyl isoindolinone from N-ethynyl phthalimide. 
Reagents/Conditions: (a)Al/HgCl2/THF:H2O (9:1)/RT/30 min (b) Thiophenol(1.2)/TsOH/ 
DCM/RT/24 hr. 
As well, attempts to synthesize “click” EM-12 from “click” thalidomide was 
explored in an approach similar to the conversion of thalidomide to EM-12 (Scheme 8). 
The approach is comparable that attempted when converting N-ethynyl phthalimide to 
isoindolinone. First, the glutarimide nitrogen of the “click” thalidomide is protected with 
p-methoxybenzyl chloride (PMB) in order to reduce the reactivity of the glutarimide ring. 
After protection of the glutarimide with the PMB group, a chemoselective aluminum 
amalgam-mediated reduction of the phthalimide to the hydroxy lactam, followed by 
phenylthiation and desulfurization would yield “click” EM-12. The base-mediated 
protection of “click” thalidomide with p-methoxybenzyl chloride was accomplished with 
cesium carbonate in acetonitrile over 16 hr. The crude reaction mixture was purified to 
yield PMB “click” thalidomide 92 as a crystalline product in modest yield (48%). 
Following the protection, 92 was exposed an aluminum amalgam (Al/Hg), aluminum strips 







and the N-PMB hydroxylactam 93 was afforded as the only product with no observable 
reduction of the glutarimide carbonyls. Direct treatment of 93 with thiophenol in 
dichloromethane with p-toluenesulfonic acid (catalytic) gave no detectable thiolated 
product by NMR.  
Scheme 8. Proposed synthesis of “click” EM-12 from the “click” thalidomide. Reagents 
conditions (a)PMB-Cl(1.2 equiv)/MeCN/RT/6 hr(48%) (b)Al/HgCl2/THF:H2O (9:1)/RT/ 









Scheme 9. Click reaction mechanism to generate the 1,4-substituted 1,2,3-triazole. 
Figure 15. Regiochemistry of cycloaddition chemistry could yield either 1,4- or 1,5-
substituted “click” thalidomide analogues. 
The regiochemistry of dipolar cycloaddition click reactions have the ability to yield 
one of two products, 1,4- or 1,5- triazole substitution among the ring (Figure 15). The click 
thalidomide analogues (81-82, 87-88) display the 1,4- substitution on the 1,2,3-triazole 
ring. The 1,4- substitution is a result of the copper (I) catalyst mediating a dinuclear copper 




Synthetic routes to click thalidomide analogues are detailed utilizing a novel 3-
azidoglutarimide. The direct and homomethylene analogues of click thalidomide were 
done through the dipolar cycloaddition reaction with known N-ethynyl/propargyl 
phthalimide. In synthesizing the EM-12 derivatives, N-ethynyl/propargyl isoindolinones 
weas synthesized to create the direct and homomethylene analoge of EM-12. To further 
explore the reactivity of 3-azidoglutarimide, analogues encompassing the fluorinated aryl 
acetylenes were chosen to mimic the electronic effects of the phthalimide group. The click 
thalidomide analogues will be evaluated in a full range of bioassay types. (For publication 
see Appendices p. 271) 
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Experimental 
General. Solvents and reagents are ACS grade and were used as commercially supplied. 
Analytical thin-layer chromatography (TLC) utilized 0.25 mm pre-cut glass-backed plates 
(Merck, Silica Gel 60 F254). Thin-layer chromatograms were visualized during 
chromatographic and extraction runs by rapidly dipping the plates in 
anisaldehyde/ethanol/sulfuric acid stain or phosphomolybdic acid/ ethanol stain and 
heating (hot plate). Gravity-column chromatography was carried out using silica gel 60 (E. 
Merck 7734, 70-230 mesh). Flash-column chromatography was carried out using silica gel 
60 (E. Merck 9385-9, 230-400 mesh) using compressed nitrogen. Nuclear magnetic 
resonance (1H and l3C NMR) spectra were recorded with Varian VNMRS 400, 500, or 700 
MHz instruments using CDCl3 as a solvent and TMS as internal standard. Infrared spectra 
(FTIR) were recorded with a PerkinElmer Spectrum 100 instrument and spectral values are 
reported as cm-1.  
3-Azidopiperidine-2,6-dione. 66 
To a 48 mL glass pressure reaction vessel fitted with a Teflon screw cap was added 
piperidine-2,6-dione (2.00 g, 17.7 mmol) and Br2 (2.82 g, 0.90 mL, 17.7 mmol) in 
chloroform (15 mL). The reaction mixture was then heated in a Kugelröhr oven at 110 °C 
(45 min). The solvent was removed and the crude bromoglutarimide, 65, was then 
dissolved in acetone (5 mL) followed by the addition of sodium azide (3.44 g, 53.1 mmol) 
whereupon the reaction mixture turned blue-purple. The reaction mixture was stirred at 
room temperature (24 h) and then directly applied to a gravity silica gel column. Elution 
with hexane/ethyl acetate (1:1) gave a mixture of unreacted 65 and product 66 (1:1). The 
mixture of 66 and unreacted 65 was again dissolved in acetone (5 mL) and sodium azide 
34 
(1.15 g, 17.7 mmol) was added and stirring of the blue-purple reaction mixture was 
continued at room temperature (24 h). Column chromatography (hexane/ethyl acetate, 1:1) 
of the reaction mixture gave pure 3-azidopiperidine-2,6-dione, 66, as an off-white 
amorphous solid (1.44 g, 53% from glutarimide): mp 144-145 C; Rf 0.24 (TLC stains blue 
with heat); 1H NMR (400 MHz, CDCl3) d 4.21 (dd, J=9.6 Hz, 8.4 Hz, 1H), 2.78 (dt, J=18.4 
Hz, 5.6 Hz, 1H) 2.63-2.54 (m, 1H), 2.23-2.16 (m, 1H), 2.04-1.95 (m, 1H). 13C NMR (400 
MHz, CDCl3) d 170.7, 169.2, 58.2, 29.1, 24.0. FTIR (neat) 3090, 2112, 1710, 1676 cm-1; 































































General procedure for the preparation of click compounds: 72-76 
To a stirred solution of 3-azidopiperidine-2,6-dione, 66 (20.0 mg, 0.13 mmol) and 
arylalkyne 67-71 (0.143 mmol) in tetrahydrofuran (750 mL) was added aqueous copper 
sulfate (52 mM, 0.013 mmol, 250 mL). Sodium ascorbate (12.8 mg, 0.065 mmol) was then 
added ten minutes after the addition of the CuSO4 solution. The reaction mixture was 
stirred (16 h) at room temperature followed by direct application to a gravity silica gel 
column and elution with chloroform/methanol (95:5). Combination and concentration of 
the chromatographic fractions gave the pure triazoles 72-76 as white or off-white 
amorphous solids. 
3-(4-Phenyl-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione. 72 
3-(4-Phenyl-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione 72 was obtained as a white 
amorphous solid (26 mg, 78%): mp 208-210  °C; Rf 0.28 (chloroform/methanol, 9:1); 1H 
NMR (400 MHz, DMSO-d6) d 11.25 (s, 1H), 8.66 (s, 1H), 7.82-7.84 (d, J=7.2 Hz, 2H), 
7.42-7.46 (m, 2H), 7.30-7.34 (m, 1H), 5.84 (dd, J=13.2, 5.2 Hz, 1H), 2.83-2.91 (m, 1H) 
2.65-2.76 (m, 2H) 2.34-2.36 (m, 1H); 13C NMR (100 MHz, DMSO-d6): d 172.8, 169.9, 
146.7, 131.0, 129.4, 128.4, 125.5, 122.0, 59.6, 31.1, 24.8: IR (neat) 3090, 2930, 1732, 1699, 






















































































































3-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)piperidine- 2,6-dione. 73  
3-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione 73 was obtained as a 
white amorphous solid (64 mg, 94%): mp 221-222 °C; Rf 0.32 (chloroform/methanol, 9:1); 
1H NMR (400 MHz, DMSO-d6) d 11.24 (s, 1H), 8.64 (s, 1H) 7.84-7.88 (m, 2H)  
7.25-7.30 (m, 2H), 5.83 (dd, J=12.4, 4.8 Hz, 1H), 2.82-2.90 (m, 1H), 2.62-2.70 (m, 2H), 
2.32-2.35 (m, 1H) 13C NMR (100 MHz, DMSO- d6): d 172.8, 169.8, 163.5, 161.0, 145.8, 
127.6 (d, J=7.6 Hz), 122.0, 116.4 (d, J=22.0 Hz), 59.6, 31.1, 24.8. IR (neat) 3194, 3105, 
2916, 1731, 1708 cm-1. HRMS (ESI-TOF) m/z [M+H]+; calcd for C13H12FN4O2: 275.0944, 





































































































































3-(4-(3-Fluorophenyl)-1H-1,2,3-triazol-1-yl)piperidine- 2,6-dione. 74  
3-(4-(3-Fluorophenyl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione 74 was obtained as a 
white solid (35 mg, 98%): mp 199-201 °C; Rf 0.375 (chloroform/methanol, 9:1); 1H NMR 
(400 MHz, DMSO-d6) d 11.25 (s, 1H), 8.74 (s, 1H), 7.65-7.69 (m, 1H), 7.46-7.51 (m, 2H), 
7.13-7.18 (m, 1H), 5.85 (dd, J=12.4, 4.4 Hz, 1H), 2.83-2.89 (m, 1H), 2.62-2.71 (m, 2H), 
2.34-2.37 (m, 1H) 13C NMR (100 MHz, DMSO-d6): d 172.9, 169.8, 164.2, 161.8, 145.7, 
132.4 (d, J=154.9 Hz), 122.9, 121.6, 115.2 (d, J=21.3 Hz), 112.1 (d, J=15.9 Hz), 59.7, 31.1, 
24.8. IR (neat) 3098, 2917, 2853, 1732, 1705 cm-1. HRMS (ESI-TOF) m/z [M+H]+; calcd 













































































































































3-(4-(2-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl) piperidine-2,6-dione. 75  
3-(4-(2-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione 75 was 
obtained as a white solid (36 mg, 84%): mp 155-157 °C; Rf 0.37 (chloroform/methanol, 
9:1); 1H NMR (400 MHz, DMSO-d ) d 11.23 (s, 1H), 8.41 (s, 1H), 7.74-7.85 (m, 3H), 7.60-
7.63 (m, 1H), 5.89 (dd, J=12.8, 5.2 Hz, 1H), 2.83-2.90 (m, 1H), 2.65-2.78 (m, 2H), 2.31-
2.36 (m, 1H) 13C NMR (100 MHz, DMSO- d6): d 172.9, 169.8, 143.7, 133.1, 132.2, 129.8 
(q, J=2.2 Hz), 129.3, 126.8 (q, J=30.4 Hz), 126.7 (q, J=6.1 Hz), 124.8 (q, J=3.1 Hz), 124.4 
(q, J=271.8 Hz), 59.7, 31.2, 24.8. IR (neat) 3220, 3094, 2957, 1732, 1701 cm-1. HRMS 





























































































































































3-(4-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione. 76  
3-(4-(3,5-bis(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione 76 was 
obtained as a white solid (38 mg, 76%): mp 115-117 °C; Rf 0.29 (chloroform/methanol, 
9:1); 1H NMR (400 MHz, DMSO-d6) d 11.29 (s, 1H), 9.07 (s, 1H), 8.50 (s, 2H), 8.07 (s, 
1H), 5.91 (dd, J=12.8, 5.2 Hz, 1H), 2.84-2.89 (m, 1H), 2.66-2.73 (m, 2H), 2.38-2.41 (m, 
1H) 13C NMR (100 MHz, DMSO-d6): d 172.8, 169.7, 144.1, 133.5, 131.5 (q, J=32.6 Hz), 
125.7, 124.2, 123.2 (q, J=271.9 Hz), 121.7, 59.8, 31.1, 24.7. IR (neat) 3219, 3094, 2872, 














































































































































2-(Prop-2-yn-1-yl)isoindoline-1,3-dione. 78  
Prepared by the method of Clayton (69%):67 mp 146-148 °C (Lit.36 149-150 °C). The 
spectroscopic data was consistent with the literature:67 1H NMR (400 MHz, CDCl3) d 7.80-
7.91 (m, 2H), 7.74-7.76 (m, 2H), 4.47 (s, 2H), 2.24 (s, 1H).  
2-(Prop-2-yn-1-yl)isoindolin-1-one. 80 
Isoindolin-1-one 21 (250 mg, 1.85 mmol) was dissolved in acetonitrile (9 mL) and cesium 
carbonate (2.40 g, 7.39 mmol) was added followed by propargyl bromide (308 mL, 2.77 
mmol). The reaction mixture was stirred at reflux (2 h). The reaction mixture was then 
dissolved in CH2Cl2 (10 mL) and washed with water (315 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated under reduced pressure. Gravity-column 
chromatography of the residual oil (hexane/ethyl/acetate, 2:1) gave 80 as a yellow solid 
(205 mg, 65%): mp 79-81 °C; Rf 0.66 (ethyl acetate); 1H NMR (400 MHz, CDCl3) d 7.82 
(d J=8.0 Hz, 1H), 7.52 (dd J=8.0, 7.2 Hz, 1H) 7.41-7.45 (m, 2H), 4.47 (s, 2H), 4.24 (s, 2H), 
2.28 (s, 1H). 13C NMR (100 MHz, CDCl3) d 167.9, 141.2, 132.1, 131.6, 128.1, 123.8, 
122.8, 78.1, 72.5, 49.1, 31.7. IR (neat) 3290, 3243, 2118, 1701 cm-1; HRMS (ESI-TOF) 






























































































2-(2-(Trimethylsilyl)ethynyl)isoindoline-1,3-dione. 83  
Prepared by the method of Davies (59%):65 mp 92-94 °C (Lit.65 94-96 °C). The 
spectroscopic data was consistent with the literature:65 1H NMR (400 MHz, CDCl3) d 7.90-
7.93 (m, 2H), 7.78-7.81 (m, 2H), 0.273 (s, 9H).  
2-(2-(Trimethylsilyl)ethynyl)isoindolin-1-one. 85 
To a 250 mL round bottom flask Cu(OAc)2 (76.4 mg, 0.42 mmol), isoindolin-1-one (1.00 
g, 7.51 mmol), Na2CO3 (216 mg, 4.2 mmol), and 4 Å molecular sieves (2.0 g) were 
combined. A solution of pyridine (324 mL, 4.2 mmol) in toluene (30 mL) was added to the 
reaction flask followed by sweeping with three volumes of O2. The reaction flask was 
placed in an oil bath and stirred for 1 h (70 °C) until the reaction mixture was a bright green 
color. A solution of ethynyltrimethylsilane (298 mL, 2.1 mmol) in dry toluene (2 mL) was 
added to the mixture over 30 min. The reaction mixture was allowed to stir (4 h) during 
which time the reaction mixture changed to a black suspension. The reaction mixture was 
filtered through Celite®, concentrated under reduced pressure and purified by flash column 
chromatography (hexane/ethyl acetate, 5:1) to yield 85 as a fluffy white amorphous solid 
(106 mg, 22%): mp 134-136 °C; Rf 0.33 (hexane/ethyl acetate, 4:1); 1H NMR (400 MHz, 
CDCl3) d 7.89 (d J=7.6 Hz, 1H), 7.62 (dd J=8.0, 7.6 Hz, 1H), 7.50 (dd, J=8.0, 7.6 Hz, 1H), 
7.44 (d J=8.0 Hz, 1H), 4.70 (s, 2H), 0.25 (s, 9H). 13C NMR (175 MHz, CDCl3) d 168.6, 
140.8, 133.0, 129.6, 128.6, 124.6, 122.8, 92.8, 75.9, 52.5, 0.18. IR (neat) 2954, 2902, 2167, 
1712 cm-1; HRMS (ESI-TOF) m/z [M+Cl]-; calculated for C13H15ClNOSi: 264.0617, 






























































































2-Ethynylisoindoline-1,3-dione. 84  
Prepared by the Method of Davies (94%):66 mp 165-169 °C (Lit.33 167-172 °C). The 
spectroscopic data was consistent with the literature:65 1H NMR (400 mHz, CDCl3) d 7.92-
7.94 (m, 2H), 7.80-7.83 (m, 2H), 3.33 (s, 1H).  
2-Ethynylisoindoline-1-one. 86  
2-(2-(Trimethylsilyl)ethynyl)isoindolin-1-one 85 (72.0 mg, 0.313 mmol) was dissolved in 
THF (3.0 mL) while stirring followed by the addition of tetra-N-butylammonium fluoride 
(TBAF, 450 mL, 1 M solution). Stirring was continued (10 min) until the reaction was 
complete as indicated by TLC. The crude reaction mixture was directly submitted to 
gravity-column chromatography (hexanes/ ethyl acetate) and afforded 86 as a white solid 
(45 mg, 92%): mp 92-94 °C; Rf 0.21 (hexane/ethyl acetate, 4:1); 1H NMR (400 MHz, 
CDCl3) d 7.91 (d, J=7.2 Hz, 1H), 7.64 (dd, J=7.2, 7.2 Hz, 1H), 7.51 (dd, J=7.2, 7.2 Hz, 
1H), 7.46 (d J=7.2 Hz, 1H), 4.71 (s, 2H), 3.08 (s, 1H). 13C NMR (175 MHz, CDCl3) d 
169.1, 140.9, 133.2, 129.4, 128.7, 124.7, 122.9, 73.9, 61.7, 52.1. IR (neat) 3268, 2931, 
2139, 1718 cm-1. Anal. Calcd for C10H7NO (157.17): C, 76.42; H, 4.49; N, 8.91; Found: 




























































































General procedure for the preparation of click products: 81-82, 87-88 
3-Azidopiperidine-2,6-dione 66 (0.25-0.5 mmol, 38-74 mg) and phthalimide or 
isoindolinone alkynes 78, 80, 84, or 86 (0.275-0.55 mmol, 1.1 equiv) were dissolved in 
25% aqueous THF (2.0 mL). The mixture was stirred (10 min) before addition of solid 
CuSO4 (0.5 equiv) and sodium ascorbate (0.5 equiv) whereupon the reaction mixture 
became a teal-colored suspension and stirring was continued (16 h). The reaction mixture 
was concentrated under rotary evaporation while absorbing onto silica gel (70-230 mesh) 
and the resulting dry residue was applied to a silica gel chromatography column.  
2-((1-(2,6-Dioxopiperidin-3-yl)-1H-1,2,3-triazol-4-yl)methyl)isoindoline-1,3-dione. 81 
The crude reaction mixture was submitted to gravity-column chromatography 
(chloroform/methanol, 97:3) to give triazole 81 as a white amorphous powder (56 mg, 
67%): mp 230-232 °C; Rf 0.44 (chloroform/methanol, 9:1); 1H NMR (400 MHz, DMSO-
d6) d 11.16 (s, 1H), 8.16 (s, 1H), 7.83-7.89 (m, 4H), 5.74 (dd, J=12.8, 8.0 Hz, 1H), 4.83 (s, 
2H), 2.75-2.80 (m, 1H), 2.56-2.63 (m, 2H), 2.20-2.23 (m, 1H). 13C NMR (100 MHz, 
DMSO-d6) d 172.8, 169.7, 167.7, 142.7, 135.0, 132.0, 123.7, 123.6, 59.5, 33.3, 31.1, 24.7. 
IR (neat) 3220, 2957, 2863, 1732, 1701 cm-1; HRMS (ESI-TOF) m/z [M+H]+; calculated 















































































































































3-(4-((1-Oxoisoindolin-2-yl)methyl)-1H-1,2,3-triazol-1- yl)piperidine-2,6-dione. 82  
The crude reaction mixture was submitted to gravity-column chromatography 
(chloroform/methanol, 97:3) to give triazole 82 as a white amorphous powder (53 mg, 
61%): mp 212-215 °C; Rf 0.39 (chloroform/methanol, 9:1); 1H NMR (400 MHz, DMSO-
d6) d 11.17 (s, 1H), 8.16 (s, 1H), 7.68 (d, J=7.2 Hz, 1H), 7.56e-.57 (m, 2H), 7.44-7.49 (m, 
1H), 5.76 (dd, J=12.8 Hz, 5.2 Hz, 1H), 4.80 (s, 2H), 4.46 (s, 2H) 2.77-2.82 (m, 1H), 2.59-
2.64 (m, 2H), 2.22-2.47 (m, 1H). 13C NMR (100 MHz, DMSO-d6) d 172.8, 169.8, 167.5, 
143.5, 142.2, 132.4, 131.9, 128.3, 123.9, 123.8, 123.3, 59.5, 49.9, 37.4, 31.1, 24.7. IR (neat) 
3063, 2916, 2836, 1704, 1666 cm-1. HRMS (ESI-TOF) m/z [M+H]+; calculated for 



















































































































































The crude reaction mixture was submitted to gravity-column chromatography 
(hexane/ethyl acetate, 1:9) to give triazole 87 as a white amorphous powder (126 mg, 83%): 
mp 289-291 °C; Rf 0.38 (THF/hexane, 2:1); 1H NMR d (400 MHz, DMSO-d6) d 11.25 (s, 
1H), 8.45 (s, 1H), 7.97-8.00 (m, 2H), 7.90-7.94 (m, 2H), 5.90 (dd J=12.8, 5.6 Hz, 1H), 
2.82-2.86 (m, 1H), 2.66-2.75 (m, 2H), 2.34-2.37 (m, 1H). 13C NMR (100 MHz, DMSO-
d6) d 172.7, 169.5, 166.5, 136.1, 135.5, 131.8, 124.2, 122.9, 60.2, 31.2, 24.6. IR (neat) 
3146, 3067, 2933, 1721, 1696 cm-1. HRMS (ESI-TOF) m/z [M+H]+; calculated for 









































































































































3-(4-(1-Oxoisoindolin-2-yl)-1H-1,2,3-triazol-1-yl)piperidine-2,6-dione. 88  
The crude reaction mixture was submitted to gravity-column chromatography 
(chloroform/methanol, 95:5) and then recrystallized with methanol to give triazole 88 as a 
white amorphous powder (70 mg, 78%): mp decomp. >300 °C; Rf 0.41 
(chloroform/methanol, 9:1); 1H NMR (700 MHz, DMSO-d6) d 11.19 (s, 1H), 8.56 (s, 1H), 
7.79 (d J=7.7 Hz, 1H), 7.67-7.71 (m, 2H), 7.53 (dd J=7.7, 7.0 Hz, 1H), 5.85 (dd J=13.3, 
5.6 Hz, 1H), 2.76-2.84 (m, 2H), 2.64-2.66 (m, 1H), 2.27-2.28 (m, 1H). 13C NMR (100 
MHz, DMSO-d6) d 172.8, 169.7, 165.6, 143.6, 142.4, 132.8, 131.6, 128.7, 124.3, 123.6, 
113.8, 60.1, 49.4, 31.2, 24.5. IR (neat) 3180, 3087, 2923, 1735, 1697 cm-1. HRMS (ESI-


































































































































PART B. AMINO ACID SYNTHESIS 
86 
Introduction 
Proteinogenic amino acids are the necessity behind the utilization for a chiral pool 
of amino acids. Of the chiral pool, 20 essential and non-essential amino acids exist that 
make up an overwhelming majority of amino acids that are proteinogenic. Outside of the 
20 essential amino acids, a bevy of unnatural amino acids have been and are currently being 
used in a range of biological applications.1 Unlike essential amino acids which can be easily 
extracted, unnatural amino acids must be synthesized to be tested for their utiliziation. 
Unnatural amino acid synthesis has been increasing dramatically in the recent decades. In 
the 1980’s there were only a handful of unnatural amino acids reported, whereas in recent 
years there have been hundreds of scientific investigations involving unnatural amino 
acids. (Figure 16). 










































Publications containing the concept
"unnatural amino acids"
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Unnatural amino acids have a number of useful properties that are exhibited in 
biological compounds ranging from altering protein functionality to use as bioconjugates 
and as reactants to prepare important drug-like molecules.2,3 There are a variety of recently-
published reactions that can be utilized to synthesize unnatural amino acids. The synthesis 
of unnatural amino acids has evolved dramatically over the years since the first published 
amino acid by Strecker in 1850.4 Amino acids are defined by the presence of three 
characteristics: an amine, an ester, and a functional side chain. Of the plethora of 
retrosynthetic approaches to unnatural a-amino acid synthesis, amino acid synthesis can  
Figure 17. Retrosynthetic approaches to a-amino acids. 
be broken down into a set group of reactions (Figure 17). The most simplistic approach 
involves chemistry directly on the side chain to synthesize unnatural amino acids. One such 
early example was performed in 1958 with the benzylation of the phenolic oxygen of L-
Imine reduction 
Alkylation Amination 
Side Chain Variation Carboxylation 
a-Amino Acid 
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tyrosine.5 Imine reduction can also be performed on an a-imino acid in which reduction 
occurs with either a hetero anion or a hydride to furnish an a-amino acid.6-8 The other 
classifications of unnatural amino acid synthesis involve the presence of two of these three 
defining characteristics and some form of chemical reaction to incorporate the final 
characteristic. Amination and carboxylation have both been shown to occur through metal 
catalysis,9-11 and amination has also been achieved under Ullman conditions.13 Alkylation 
of a-amino acids has been reviewed extensively over the last few years and is 
accomplished through the utilization of a synthon termed “glycine equivalent,” a two-
carbon fragment likely containing both a protected nitrogen and carboxylic acid.  
Unusual or unnatural amino acids are found within a large number of drugs and 
biologically active molecules. For clarity, this class of molecules is subdivided into three 
categories: the unnatural amino acid itself acting as the central component of the drug, 
unusual amino acids that are contained within linear peptides, and unusual amino acid 
within cyclic peptides (Figure 18). Of the unnatural amino acids that are central drug 
compounds, lacosamide 6 is a methoxylated serine residue that as the core scaffold. 
Lacosamide which bears the methoxylated serine residue, is an anticonvulsant that is 
approved for use in both the United States and Europe.13 Many known anticonvulsants act 
through inhibition of calcium channels. Lacosamide’s mechanism of action is currently 
unknown, although it is hypothesized that lacosamide binds to a protein that subsequently 
interacts with voltage gated sodium channels. Saxagliptin 5 contains a bulky hydroxylated 







Figure 18. A small set of biologically active structures that bear at least one and up to 








 (DDP-IV) and is used for the treatment of type II diabetes.14 Inhibitors of DDP-IV regulate 
the level of incretin, leading to a downstream effect on insulin and blood glucose levels. 
Of the bulky side groups, one of the most prevalent and commonly used unnatural amino 
acids is tert-leucine. The unnatural tert-leucine is hydrophobic, sterically bulky, and 
inflexible and occurs in both natural products and in drugs currently on the market.  
Unnatural amino acids are also used in a class of drugs that are comprised of linear 
peptides, ranging from dipeptides to polypeptide chains. Many linear peptides contain a D-
amino acid at or near the C- or N-terminus in order to be less susceptible to proteolysis. A 
decapeptide, Abarelix 1 is currently being used for treatment of prostate cancer.15 This is 
done by binding to gonadotropin-releasing hormone and decreasing testosterone levels and 
thus hindering the growth of prostate cells. Two tripeptides, asunaprevir16 and boceprevir,17 
are under investigation as potential drug candidates. Both of these drugs contain a tert-
leucine as well as a derivatized proline for the treatment of Hepatitis C Virus (HPV) 
infection. Asunaprevir 8 is currently in phase III trials and boceprevir 4 was recently 
removed from the market in favor of drugs with higher inhibitor specificity. The tripeptides 
act by inhibiting the NS3 protease that destroys downstream proteins, preventing the 
genome replication of HPV. A class of inhibitors and amino acid-based drugs are observed 
with a constrained phenylalanine derivative seen as a cyclic amino acid: quinapril,18 
farnesyl transferase inhibitor,19 and activated protein C inhibitor.20 Quinapril, 9, is currently 
being sold as an inhibitor of the angiotensin converting enzyme (ACE) which is used in 
the treatment of hypertension by allowing for production of angiotensin II.18 One of the 
core structural unnatural amino acids is a 1,2,3,4-tetrahydroisoquinoline carboxylic acid 
(Tic) derivative 13 (Figure 19a). The Tic derivative can also be seen in a pentapeptide 
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farnesyl transferase inhibitor 12 where the only unnatural amino acid is the replacement of 
a Phe with a Tic. Synthesizing an inhibitor with Tic as opposed to phenylalanine resulted 
in a more potent inhibitor of the Ras protein, a protein involved in cellular growth.19 Similar 
to the Tic derivative, another constrained amino-acid derivative observed as an inhibitor is 
an indane-based (Ind) amino acid 14 (Figure 19b). A tripeptide inhibitor of activated 
protein C containing two unnatural amino acids, a cyclohexyl-glycine derivative next to an 
Ind amino acid, could be used for hemophilic disorders.20 The tripeptide 2 was 
demonstrated to be a potent inhibitor of activated protein C which results in the generation 
of thrombin and is potentially useful as a coagulant. As well, unnatural amino acids are 
observed in the b-lactams class of antibiotics. Of these b-lactams, amoxicillin contains an 
unnatural amino acid as well as a lactam ring composed of a bicyclic dipeptide 3. 
Amoxicillin and other b-lactams have been extensively investigated and their importance 
is very well defined.21,22 
Figure 19. Two phenylalanine mimics that are reported to be used as unnatural amino 
acids are a) Tetrahydroisoquinoline carboxylic acid (Tic) derivative and b) Indane-based 
(Ind) derivative 
Outside of single amino acid drugs and linear peptide drugs, a class of cyclic 
peptide drugs exist in which the range of a single amino acid is changed to a majority of 
the cyclic peptides. Cyclic peptides are commonly observed having two cysteines to 
a) b)13 14
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provide a disulfide bridge in a few hormones, including somatostatin.  A single substitution 
to an unnatural amino acid is observed on the cyclic peptide lanreotide, a somatostatin 
receptor antagonist. Lanreotide contains a single substituted unnatural amino acid, D-2¢-
napthalalanene, on the N-terminus and is used for the treatment of acromegaly.23 Cyclic 
peptides are also formed through more than just disulfide bridges, including a depsipeptide 
which is seen in the cyclic natural product-derived peptide quinupristin 10.24 The mixture 
of quinupristin with dalfopristin is sold as the antibiotic, Synercid, in which quinipristin 
contains multiple unnatural amino acids.  
The two-carbon “glycine equivalent” containing a protecting groups do not only 
provide orthogonal protection, but also provide an increased activation for reactivity of 
neighboring atoms. Alkylation through activation of the protected glycine equivalents was 
demonstrated by O’Donnell and co-workers with the versatile benzophenone imine. The 
O’Donnell strategy utilizes the benzophenone imine, and under anhydrous or phase transfer 
catalysis, the benzophenone imine undergoes alkylation through a base-catalyzed reaction. 
Under the mildly basic conditions, the reaction afforded the racemic monoalkylated 
product (Scheme 10).25-28 Modifications of the benzophenone imine at the C-terminus were 
accomplished by utilizing either a solid phase or a polyethylene glycol to mediate a solid 
phase or liquid-phase synthesis.29 Some advantages of these approaches include a support 
to deprotect the amine and allow further chemistry to occur on the free amine. An 
asymmetric approach was initially proposed by O’Donnell utilizing chiral auxiliary 
reagents.30 
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Scheme 10. General approach by O’Donnell et al. to synthesize a-amino acids. 
Cinchonine-derived catalytic salts have been shown to generate enantiomerically 
enriched amino acid derivative. This approach was modest, generating a 66% enantiomeric 
excess (ee) and a greater enantioselective approach has been explored utilizing a range of 
chiral derivatives to give more enantioselectivity (96% - 99% ee). While utilizing the 
benzophenone imine as a nucleophile has been explored, O’Donnell also showed the 
versatility of the benzophenone imine to be an electrophile through an acetylated 
intermediate. This allowed for a nucleophile to displace the acetate on the cationic glycine 
equivalent. Similar to the enantioselective reactions performed on the anionic glycine 
equivalent, O’Donnell was the first to investigate enantioselective reactions that were 
completed with a slight enantiomeric excess on the acetylated benzophenone imine with a 
palladium catalyst and a chiral pyrrolidine auxiliary. This investigation led to the use of 
other N-substituted acetylated glycine equivalents to be utilized in an enantioselective 
reaction which gave optically enriched unnatural amino acids. A range of chiral unnatural 
amino acids were also synthesized by Myers et al. without a protected amine (Scheme 
11).31 The protected C-terminus glycinamide contains a chiral phenylpropanol which has 
a chiral induction effect, resulting in an enantioselective alkylation. A more recent 
synthesis of a,a-unnatural amino acids has been demonstrated with a glycine equivalent  
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Scheme 11. General approach by Myers et al. to synthesize a-amino acids. 
Schiff base and a Ni(II) complex.32,33 This complex synthesized by Soloshonok et al. has 
generated a range of a,a-unnatural amino acids through a base catalyzed dialkylation to 
generate a a,a-cyclic or symmetrical a,a-disubsituted glycine equivalent. The substituted 
Ni(II) glycine equivalent is easily cleaved through acid hydrolysis to give the free a,a-
unnatural amino acid. The Ni(II) complex with the tetradentate ligand has been modified 
by Brimble et al. to generate an asymmetric approach to chiral a-unnatural amino acids 
(Scheme 12).34 Enantioselective reaction was accomplished through the derivatization of 
a/the pyridine ring on the tetradentate ligand to be a substituted chiral N-benzyl pyrrolidine 
derivative. This Schiff base glycine derivative within the Ni(II) complex was observed to 
have bis-addition to give a-amino acids through a stereoselective alkylation. Similar to 
these aforementioned reactions of acyclic glycine equivalents, a class of cyclic glycine 
equivalents have also been utilized and reviewed. In the synthesis of proteinogenic and 
non-proteinogenic amino acids, it is commonly observed that many of the protecting 
groups are used to perform multiple tasks by providing orthogonal protection while also 







Scheme 12. Modified approach by Brimble et al. to synthesize enantiomerically pure a-
amino acids. 
Protecting groups are not a necessity, as demonstrated by Myers and coworkers,31 
but are commonly used in synthesizing a-amino acids and must undergo deprotection in a 
one or two step process in order to obtain the amino acid. When a multistep deprotection 
is necessary, the conditions required to deprotect can generally be less harsh than a one-
step deprotection of the large protecting groups usually used in amino acid synthesis. An 
N-isoindolinone falls under a multistep deprotection, having the ability to undergo 
oxidation to yield a N-phthaloyl group. The N-isoindolinone group allows the activation of 
the a-methylene of an ethyl- or a tert-butyl ester under basic conditions so that side chains 
may be installed. The anionic glycine equivalent provides installment of a side chain with 
a reactive electrophile such as an alkyl or benzyl halide. The newly-formed alkylated N-
isoindolinone is then selectively oxidized to a removable N-phthaloyl group that has been 
utilized as a protecting group for peptide chemistry. Detailed studies including the scope 
of the alkylation reaction and the response of selected substrates to the benzylic oxidation 
of the N-isoindolinone moieties are reported herein.35  
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Results and Discussions 
Our preparation of N-isoindolinone derived esters is the initial building block for 
this novel synthesis of amino acids (Scheme 13). The addition of sodium hydride (NaH) 
to N-isoindolinone 13 in THF generates the sodium salt which then reacts with either ethyl 
bromoacetate or tert-butyl bromoacetate to synthesize either ethyl 2-(1-oxoisoindolin-2-
yl)acetate or tert-butyl 2-(1-oxoisoindolin-2-yl)acetate 14/15 respectively.36 Both 
compounds, ethyl 14 (78%) and tert-butyl 15 (97%), were obtained in good yields after 
column chromatography on silica gel (Scheme 13).   
Scheme 13. Preparation of N-isoindolinone esters. Reagents/Conditions: (a) NaH/ethyl 
bromoacetate/ 20 °C/ 16 h (78%) (b) NaH/tert-butyl bromoacetate/ 20 °C/ 16 h (78%) 
The alkylation of both compounds is mediated through lithium hexamethyl 
disilazide (LiHMDS) which generates the anion for alkylation with an electrophile. 
LiHMDS (1.05 to 1.5 equiv) is added to the mixture of ester and electrophile in THF. Bases 
with increasing strength were explored; cesium carbonate, sodium ethoxide and potassium 
tert-butoxide, but under similar conditions but gave little to no encouraging results as only 
starting materials were observable by TLC. The selected bases were explored due to the 








desired carbon a to the ester and the undesired carbon a to benzene.37,38 While other bases 
showed no promise in anion generation, LiHMDS generates both the desired and undesired 
anion when used in excess and was a byproduct from the reactions (Scheme 14). If 
multialkylated byproduct were generated and observed by TLC, purification by column 
chromatography was done to isolate desired product.  
Scheme 14. Preparation of the mono-alkylation of the N-isoindolinone amino acid 
derivative. Reagents and conditions: (a) LiHMDS/R1-X (X = C1,Br I)/THF/-78 °C to 
rt/1–16 h. 
A range of electrophiles was used to demonstrate the scope of the base-mediated 
alkylation of the isoindolinone esters (Table 4.). More specifically, the reactivity and yield 
were in part dependent upon the reactivity of the electrophile, with the most reactive 
electrophiles giving products readily and in good yield. When using less reactive 
electrophiles, the reaction did not go to completion as readily as with more reactive 
electrophiles and thus resulted in what appeared to be starting ester decomposition with a 
poorer overall yield. This was the basis for switching from the starting protected ethyl ester 
to the tert-butyl ester in an attempt to utilize a starting material with a more robust 
protecting group. A grouping to easily classify the range of electrophiles is the alkyl 
iodides, yielding primary and secondary esters (70-86%), the allyl/propargyl bromides, 
yielding the allyl/propargyl ester products (93 and 78% respectively), and lastly the 




the reaction conditions and the protocol, an equivalent of base was added to each reaction 
and stirred while monitoring by TLC. An additional amount of base was added in intervals 
to push the reaction to completion and thereby required a different amount of base for each 
alkyl halide. The requirement for additional base may be due to moisture hindering the 
strength of the base. 
Table 4. Alkylation of the N-isoindolinone protected esters 


























aReagents/Conditions: LiHMDS/THF/then R1-X (X = Cl, Br, I)/-78 C to rt/1–16 h. 
bYields are of isolated, chromatographically pure products. cAlkyl iodide was used. 
dAlkyl bromide was used. eAlkyl chloride was used. fEthyl ester was used. gtert-Butyl 
ester was used.  
In synthesizing the N-phthaloyl protected amino acid, a benzylic oxidation to 
convert the isoindolinone to the phthalimide was explored (Table 5).39,40 A host of 
reagents/conditions such as; MCPBA (m-chloroperbenzoic acid) with a combination of 
oxygens, or 2,2¢-bipyridinium chlorochromate (BPCC)/MCPBA, SeO2, Oxone®/KI, were 
used in evaluating the benzylic oxidation of the isoindolinone and were either unreactive 
or yielded complex mixtures.41 An optimal set of reaction conditions using Oxone®/KBr in 
acetonitrile:water yielded the desired corresponding N-phthaloyl products. The alkylated 
compounds were dissolved in acetonitrile-H2O (9:1) and Oxone® (5 equiv.) with potassium 
bromide (0.5 equiv.) added and allowed to stir for 16 hours at an elevated temperature (40-
45 °C). The crude reaction mixture was concentrated and extracted from water with 
dichloromethane, and then reconcentrated followed by purification by gravity column 
chromatography. The alkylated products were all evaluated, as well the starting unalkylated 
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isoindolinone to represent a “glycine equivalent,” in their ability to undergo the benzylic 
oxidation and produce the N-phthaloyl ester. The benzylic oxidation using Oxone®/KBr 
yielded the corresponding imide in a straightforward process. However, some alkylated 
isoindolinone products afforded anomalous or unexpected results.  
Table 5. Oxidation of the N-isoindolinone esters to yield N-phthaloyl amino acid 
derivatives. 
Reactant Product Yield% 
15 27 85 
16 28 70 
17 29 76 
18 30 98 
19 31 80 
20 32 NR 
a.
. 27-36 15-24 
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21 33 NR 
22 34 88 
23 35 72 
24 36 NR 
aReagents/Conditions: Oxone®/KBr/MeCN/H2O/40–45 °C/16 h. bYields are of isolated 
chromato-graphically-pure product. 
A majority of the substrates underwent oxidation to give the desired product, but 
the allyl, propargyl, and para-mehtoxybenzyl side chain products 32, 33, and 36 failed to 
respond to oxidation with Oxone®/KBr system. The inability for these alkylated 
isoindolinones to undergo benzylic oxidation is likely due to the electron rich side chains 
which promoted unwanted reactions. Of the reactions that underwent oxidation, two 
compounds gave unexpected results after oxidation. The naphthalene methyl isoindolinone 
underwent oxidation with the optimized conditions to yield the benzylic oxidation as 
expected (80%), but bromination of the naphthalene ring in the 2-positionto give 37 was 
observed as well (Scheme 15).  
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Scheme 15. Benzylic oxidation of isoindolinone napthalene derivative unexpected 
product. a.) Oxoneâ IBX/KBr/MeCN- H2O/40–45 °C/3 h 
Isoindolinone ethyl ester 14 was used with LiHMDS and 2-bromomethyl-4,5-
diphenyloxazole42 to yield an isoindolinone oxazole ethyl ester derivative that was isolated 
in moderate yield (63%). The b-oxazol-2-yl-(methyl)-isoindolinone derivative 38 was 
anticipated to be used as a masked carboxylic acid containing two different protecting 
groups for each carboxylic acid and after oxidation the oxazole could be deprotected to 
generate the phthaloyl protected aspartic acid derivative (Figure 20).43  







Oxidation of the b-oxazol-2-yl-(methyl)-isoindolinone derivative using Oxoneâ/KBr in 
acetonitrile/water resulted in the oxidation of the isoindolinone to the pththaloyl. An 
unexpected result of the oxidation was the oxazole cleavage to generate the N-
phthaloylasaparine ethyl ester 39 (65%) (Scheme 16). 
Scheme 16. Benzylic oxidation of isoindolinone oxazole derivative unexpected product. 
a.) Oxineâ/KBr/MeCN- H2O/40–45 °C/3 h 
The greatest determinant for confirming the transformation is through 1H NMR 
spectroscopy. Analyzing the starting isoindolinone through 1H NMR, the isoindolinone 
benzylic methylene protons exhibits a signature AB quartet around 4.0-5.0 ppm. Upon 
oxidation, the disappearance of the AB quartet and a subsequent emergence of the classic 






Figure 21. The observational difference in 1H NMR of the starting phenyl isoindolinone 
(left) to the oxidation N-phthaloyl phenylalanine derivative (right). 
To demonstrate the applicability of N-phthaloyl protected amino acids, the N-
phthaloyl phenylalanine tert-butyl ester was converted to a commercially available N-BOC 
phenylalanine tert-butyl ester amino acid derivative (Scheme 17). A change of N-phthaloyl 
to N-BOC was first done through deprotection of the phthaloyl. Deprotection was 
accomplished by adding N-phthaloyl phenylalanine derivative to hydrazine hydrate 
Scheme 17. Conversion of N-phthaloyl phenylalanine to a standard N-BOC phenylalanine 
derivative. Reagents/Conditions: (a) N2H4/MeOH-H2O/rt/16 h. (b) di-tert-butyl 
dicarbonate/NaHCO3/dioxane/rt/16 h (81%, over two steps). 
 (10 equiv.) in methanol. The reaction mixture was stirred for 16 h then immediately 
concentrated. The residue was resuspended in dichloromethane to precipitate the free 




.34 40 41 
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and sodium dicarbonate was added followed by tert-butyl dicarbonate at room temperature. 
Stirring was continued (16 h) and upon completion, the mixture was extracted with 
dichloromethane. The organic layer was submitted to gravity-column chromatography to 
afford pure N-BOC phenylalanine tert-butyl ester 41 (81% over two steps). 
Conclusion 
The applicability of an isoindolinone acting as both a functional group and at 
activating the orthogonal carbon for further reactions was demonstrated. The N-
isoindolinone groups as a nitrogen protector allowed for selective alkylation and underwent 
benzylic oxidation to give the N-phthaloyl group. This approach is the basis for a starting 
point of a-amino acid construction. The oxidation conditions were detrimental to some of 
the electron-rich substrates, the vinyl- ethynyl- alanine derivatives, and the methoxy 
phenylalanine derivative did not respond to oxidation. The applicability of N-isoindolinone 
to act as a protecting group for amino acid synthesis has been demonstrated and asymmetric 
variants could be explored in future studies. (For publication see Appendices p. 277) 
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Experimental 
General. Solvents and reagents were ACS grade and were used as commercially supplied. 
Analytical thin-layer chromatography (TLC) utilized 0.25 mm pre-cut glass-backed plates 
(Merck, Silica Gel 60 F254). Thin-layer chromatograms were visualized during 
chromatographic and extraction runs by rapidly dipping the plates in 
anisaldehyde/ethanol/sulfuric acid stain or phosphomolybdic acid/ ethanol stain and 
heating (hot plate). Gravity-column chromatography was carried out using silica gel 60 (E. 
Merck 7734, 70-230 mesh). Flash-column chromatography was carried out using silica gel 
60 (E. Merck 9385-9, 230-400 mesh) using compressed nitrogen. Nuclear magnetic 
resonance (1H and l3C NMR) spectra were recorded with Varian VNMRS 400, 500, or 700 
MHz instruments using CDCl3 as a solvent and TMS as internal standard. Infrared spectra 
(FTIR) were recorded with a PerkinElmer Spectrum 100 instrument and spectral values are 
reported as cm-1. 
Synthesis of Substituted Isoindolinone Substrate Esters (14, 15) for Alkylation: 
Ethyl 2-(1-oxoisoindolin-2-yl)acetate. 14 
A solution of isoindolin-1-one (1.00 g, 7.51 mmol) in freshly-distilled THF (25 mL) was 
added slowly to a suspension of sodium hydride (450 mg, 11.26 mmol, freshly washed 
with hexane) in THF (25 mL) under N2 at 0 °C and stirring was continued (30 min). To the 
reaction mixture ethyl bromoacetate (1.24 mL, 11.26 mmol) was slowly added and the 
resulting reaction mixture was allowed to stir at room temperature (16 h). The reaction 
mixture was quenched with methanol and concentrated. The obtained crude residue was 
further purified by gravity column chromatography (hexane/ethyl acetate, 2:1) provided 
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pure 14 as an off-white solid (1.39 g, 78%); mp = 77-79 °C (Lit. mp = 78-80 °C). 1H NMR 
(400 MHz, CDCl3) δ 7.87-7.85 (d, J = 7.6 Hz, 1H), 7.57-7.53 (m, 1H), 7.48-7.44 (m, 2H), 
4.518 (s, 2H), 4.39 (s, 2H), 4.22 (q, J = 6.8 Hz, 2H), 1.28 (t, J = 6.8 Hz, 3H) ppm. The 
spectroscopic data was consistent with that previously reported.35 
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tert-Butyl 2-(1-oxoisoindolin-2-yl)acetate. 15 
To a suspension of sodium hydride(450 mg, 11.26 mmol), freshly-washed with hexane, in 
freshly-distilled THF (25 mL), isoindolin-1-one (1.00 g, 7.51 mmol) was slowly added a 
solution in THF (25 mL) under an N2 atmosphere at 0 °C and stirred for 30 min. To the 
resulting reaction mixture tert-butyl bromoacetate (1.66 mL, 11.26 mmol) was added and 
stirring was continued at room temperature (16 h). The reaction mixture was carefully 
quenched with methanol and concentrated to obtain a crude residue. The crude product was 
then further purified by column chromatography (hexanes/ethyl acetate, 4:1) to afford pure 
15 as an off-white solid (1.80 g, 97%); mp = 62-64 °C; Rf = 0.33 (hexane/ethyl acetate, 
2:1); 1H NMR (400 MHz, CDCl3) δ 7.87-7.85 (d, J = 7.6 Hz, 1H), 7.54-7.52 (m, 1H), 7.47-
7.43 (m, 2H), 4.51 (s, 2H), 4.29 (s, 2H), 1.46 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3) δ 
168.8, 168.1, 141.6, 131.9, 131.6, 127.9, 123.9, 122.7, 82.2, 50.5, 44.5, 28.1 ppm. ); FT-






























































































Procedures for the Alkylation of Isoindolinone Esters 14 and 15: 
Ethyl 2-(1-oxoisoindolin-2-yl)propanoate. 16 
To a solution of ethyl 2-(1-oxoisoindolin-2-yl) acetate 14 (50 mg, 0.228 mmol) in dry THF 
(5.0 mL) iodomethane (22 µL, 0.684 mmol) was added at room temperature under 
nitrogen. Stirring was continued (10 min) and lithium hexamethyldisilazide (1.0M, 301µL, 
301 mmol) in THF was added dropwise by syringe to the reaction mixture under N2 
atmosphere resulting to yellow solution. The reaction mixture was stirred (16h) at room 
temperature. After reaction completion as indicated by TLC, it was quenched with 
saturated aqueous ammonium chloride solution (5 mL) and extracted with dichloromethane 
(3 x 10 mL). The organic extracts were combined, dried over anhydrous sodium sulfate 
and concentrated to obtain a crude residue. Further purification was performed using flash 
column chromatography (hexane/ethyl acetate, 4:1) to give pure 16 as a colorless oil (39 
mg, 73%); Rf = 0.49 (hexanes/ethylacetate, 1:1); 1H NMR (700 MHz, CDCl3) δ 7.86 (d, J 
= 7.2 Hz, 1H), 7.55-7.54 (m, 1H), 7.47-7.46 (m, 2H), 5.20-5.19 (q, J = 7.0 Hz, 1H), 4.60 
(d, J=16.1Hz, 1H), 4.41 (d, J=16.1Hz, 1H), 4.18 (q, J = 3.5 Hz, 2H), 1.57 (t, J = 3.5 Hz, 
3H), 1.25 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (175 MHz, CDCl3) δ 171.8, 168.6, 141.6, 
132.2, 131.5, 127.9, 123.9, 122.8, 61.4, 49.2, 46.7, 15.9, 14.1 ppm; FT-IR (neat) 2980, 

















Ethyl 2-(1-oxoisoindolin-2-yl)butanoate. 17 
Ethyl 2-(1-oxoisoindolin-2-yl)acetate 14 (50 mg, 0.23 mmol) was dissolved in freshly-
distilled THF (2.0 mL) and the mixture was cooled to -5 °C. To the clear solution, 
iodoethane (90 µL, 1.140 mmol) was added and stirring was continued (10 min).  Lithium 
hexamethyldisilazide (1.0M, 242µL, 0.242 mmol) in THF was added dropwise by syringe 
to the reaction mixture under nitrogen which resulted in a yellow solution. The reaction 
was stirred (2h) at -5 to 0 °C, brought up to room temperature, quenched with saturated 
aqueous ammonium chloride solution (5 mL) and extracted with dichloromethane (3 x 10 
mL). The extracts were combined, dried over anhydrous sodium sulfate, and concentrated 
to give a crude residue. Submission of the residue to flash-column chromatography 
(hexane/ethyl acetate, 3:1) gave pure 17 as colorless oil (40 mg, 70%); Rf = 0.62 
(hexanes/ethylacetate, 1:1); 1H NMR (700 MHz, CDCl3) δ 7.87 (d, J = 7.2 Hz, 1H), 7.56-
7.54 (m, 1H), 7.47-7.45 (m, 2H), 5.02-5.00 (m, 1H), 4.66-4.64 (m, 1H),  4.65 (d, J=16.1Hz, 
1H), 4.35 (d, J=16.1Hz, 1H), 4.17 (q, J = 7.0 Hz, 2H), 2.16-1.83 (m, 2H), 1.25 (t, J = 7.0 
Hz, 3H), 0.96 (t, J = 7.0 Hz, 3H) ppm; 13C NMR (175 MHz, CDCl3) δ 171.5, 169.2, 141.7, 
132.1, 131.5, 127.9, 123.9, 122.8, 61.3, 61.2, 55.1, 46.7, 46.7, 23.3, 14.2, 10.8 ppm; FT-IR 


















tert-Butyl 2-(1-oxoisoindolin-2-yl)pentanoate. 18 
1-iodopropane (197 µL, 2.0 mmol) was  added to solution of tert-Butyl 2-(1-oxoisoindolin-
2-yl)acetate 15 (100 mg, 0.404 mmol) in freshly-distilled THF (2.0 mL) at -5 °C under N2 
and the reaction mixture was stirred. Lithium hexamethyldisilazide (1.0M, 484 µL, 0.484 
mmol) in THF was added dropwise by syringe to the reaction mixture under N2. The 
resulting pale-yellow reaction mixture was stirred (-5 to 0 °C, 5 h) then brought to room 
temperature and quenched with saturated aqueous ammonium chloride solution (5 mL). 
The reaction mixture was extracted with dichloromethane (3 x 10 mL). The  extracts were 
combined, dried over anhydrous sodium sulfate and concentrated to give crude product 
which was purified by flash column chromatography (hexanes/ethyl acetate, 4:1) to afford 
18 as a white solid (104 mg, 86%); mp =  70-72 °C; Rf  = 0.62 (hexanes/ethyl acetate, 1:1); 
1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 7.2 Hz, 1H), 7.54-7.50 (m, 1H), 7.45-7.43 (m, 
2H), 5.01-4.97 (m, 1H), 4.67 (d, J=16.4Hz, 1H), 4.32 (d, J=16.4Hz, 1H), 2.02-1.97 (m, 
1H), 1.81-1.78 (m, 1H), 1.42 (s, 9H), 1.37-1.30 (m, 2H), 0.94 (t, J = 6.0 Hz, 3H) ppm; 13C 
NMR (100 MHz, CDCl3) δ 170.9, 169.1, 141.8, 132.2, 131.4, 127.8, 123.9, 122.7, 81.8, 
77.3, 77.0, 76.7, 53.9, 46.7, 32.0, 28.0, 19.5, 13.5 ppm; FT-IR (neat) 2963, 2934, 2874, 

















 tert-Butyl 2-(1-oxoisoindolin-2-yl)hexanoate. 19 
1-iodobutane (230 µL, 2.0 mmol) was added to a solution of tert-butyl 2-(1-oxoisoindolin-
2-yl) acetate 15 (100 mg, 0.404 mmol) in dry THF (2.0 mL at -5 °C under N2 and stirring 
was continued (10 min). To the clear solution, lithium hexamethyldisilazide (1.0M, 484 
µL, 0.484 mmol) in THF was added dropwise by syringe. The yellow reaction mixture was 
stirred (5h) at -5 to 0 °C then brought to room temperature.    Saturated aqueous ammonium 
chloride solution (5 mL) was then added and the reaction mixture was extracted with 
dichloromethane (3 x 10 mL) The organic layers were combined, dried over anhydrous 
sodium sulfate and concentrated to   afford a crude residue which was submitted to gravity 
column chromatography (hexane/ethyl acetate, 15:1). Pure 19 was obtained as a white solid 
(96 mg, 78%);  mp = 75-77 °C; Rf  = 0.64 (hexanes/ethyl acetate, 1:1); 1H NMR (400 MHz, 
CDCl3) δ 7.86 (d, J = 7.2 Hz, 1H), 7.53-7.51 (m, 1H), 7.46-7.45 (m, 2H), 5.00-4.96 (m, 
1H), 4.67 (d, J=16.4Hz, 1H), 4.32 (d, J=16.4Hz, 1H), 1.42 (s, 9H) 1.42-1.24 (m, 4H), 0.87 
(t, J = 6 .0 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ 170.9, 169.1, 141.8, 132.2, 131.4, 
127.9, 123.9, 122.7, 81.8, 77.3, 77.0, 76.7, 54.2, 46.8, 29.6, 28.3, 28.0, 22.1, 13.8 ppm.; 
FT-IR (neat) 2958, 2932, 2872, 1732, 1688 cm -1; HRMS m/z calculated for C18H25NO3 


















































































































tert-Butyl 2-(1-oxoisoindolin-2-yl)pent-4-enoate. 20 
Allyl bromide (42 µL, 0.484 mmol) was added to a solution of tert-butyl 2-(1-
oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) in dry THF (1.0 mL) under N2 (-5 to 
0 °C) by syringe. To the clear solution, lithium  hexamethyldisilazide (1.0M, 484µL, 0.484 
mmol) in THF was added by syringe and stirring was continued (5h) in the -5 to 0 °C range. 
The reaction mixture was brought to room temperature and immediately quenched with 
saturated aqueous ammonium chloride solution (5 mL) followed by extraction with 
dichloromethane (3 x 10 mL). The extracts were combined, dried over anhydrous sodium 
sulfate and concentrated to afford a crude residue which was submitted to gravity column 
chromatography (hexane/ethyl acetate, 15:1) to give 20 as a white solid (108 mg, 93%); 
mp = 69-71 °C;     Rf = 0.61 (hexane/ethylacetate, 1:1); 1H NMR (500 MHz, CDCl3) δ 7.85 
(d, J = 7.0 Hz, 1H), 7.54-7.51 (m, 2H), 7.45-7.42 (m, 2H), 5.77-5.71 (m, 1H), 5.14-5.11 
(m, 2H), 5.03 (d, J = 10.5 Hz, 1H), 4.62 (d, J=16.0Hz, 1H), 4.31 (d, J=16.0Hz, 1H), 2.85-
2.82 (m, 1H), 2.63-2.57 (m, 1H), 1.43 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ 170.0, 
169.1, 141.8, 133.5, 132.1, 131.5, 127.8, 123.9, 122.7, 118.0, 82.2, 53.7, 47.0, 24.5, 28.0 
ppm; FT-IR (neat) 3080, 2980, 2938, 1731, 1685 cm-1; HRMS m/z calculated for 




















tert-Butyl 2-(1-oxoisoindolin-2-yl)pent-4-ynoate. 21 
 tert-Butyl 2-(1-oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) was dissolved in dry 
THF (1.0 mL) under N2 then cooled to -78 °C. A solution of lithium hexamethyldisilazide 
(1.0M, 606 µL, 0.606 mmol) in THF was added dropwise by syringe to give a yellow 
solution. Propargyl bromide (46.4 µL, 0.484 mmol) was then added dropwise by syringe 
and the reaction mixture was allowed to warm to room temperature (1h). The slightly 
orange mixture was quenched with saturated aqueous ammonium chloride solution (5 mL) 
and extracted with dichloromethane (3 x 10 mL). The concentration of the combined 
organic extracts provided crude material which was directly applied to gravity column 
chromatography (hexanes/ethyl acetate, 2:1) to yield 21 as a pale yellow oil (90 mg, 78%); 
Rf = 0.45 (hexane/ethyl acetate, 2:1); 1H NMR (700 MHz, CDCl3) δ 7.87-7.85 (d, J = 6.8 
Hz, 1H), 7.56-7.53 (m, 1H), 7.47-7.43 (m, 2H), 5.20-5.17 (dd, J = 3.2 Hz, 7.6 Hz, 1H), 
4.74 (d, J=8.4Hz, 1H), 4.62 (d, J=8.4Hz, 1H), 2.94-2.78 (m, 2H), 2.01 (s, 1H), 1.44 (s, 9H) 
ppm; 13C NMR (125 MHz, CDCl3) δ 168.9, 168.6, 141.9, 131.6, 127.9, 124.0, 122.8, 82.7, 
79.5, 71.5, 53.1, 47.7, 27.9, 20.8 ppm; FT-IR (neat) 3299, 2978, 2932, 1732, 1685 cm-1; 

















tert-Butyl 2-(1-oxoisoindolin-2-yl)-3-phenylpropanoate. 22 
tert-Butyl 2-(1-oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) was dissolved in 
freshly-distilled THF (3.0 mL) under N2 (-78 °C). Lithium hexamethyldisilazide (1.0M, 
606 µL, 0.606 mmol) in THF was added to the reaction mixture dropwise by syringe and 
stirring was continued (10 min). To the yellow solution, benzyl bromide (57 µL, 0.484 
mmol) was added dropwise by syringe which resulted in a slight discharge of color. The 
reaction was stirred (1h), brought to room temperature and immediately quenched with 
saturated aqueous ammonium chloride solution (5 mL). The mixture was extracted with 
dichloromethane (3x10 mL) and the organic layers were combined, dried over anhydrous 
sodium sulfate, and concentrated to give a crude residue.  The residue was submitted to 
flash-column chromatography (hexanes/ethyl acetate, 15:1) to provide pure 22 as a white 
solid (111 mg, 82%); mp = 94-96 °C; Rf = 0.57 (hexane/ethylacetate, 1:1); 1H NMR (400 
MHz, CDCl3) δ 7.79 (d, J = 7.2 Hz, 1H), 7.50-7.45 (m, 1H), 7.41-7.36 (m, 2H), 7.25-7.22 
(m, 4H), 7.17-7.14 (m, 1H), 5.35-5.31 (m, 1H), 4.61 (d, J=16.8Hz, 1H), 4.30 (d, J=16.8Hz, 
1H), 3.45-3.10 (m, 2H), 1.39 (s, 1H) ppm; 13C NMR (125 MHz, CDCl3) δ 170.1, 168.9, 
141.7, 136.6, 132.1, 131.4, 123.6, 127.8, 126.8, 123.9, 122.7 ppm; FT- IR (neat) 2983, 


















tert-Butyl 3-(4-fluorophenyl)-2-(1-oxoisoindolin-2-yl)propanoate. 23 
tert-butyl 2-(1-oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) was dissolved in 
freshly-distilled THF and lithium hexamethyldisilazide (1.0M, 505 µL, 0.505 mmol) in 
THF was added by syringe (-78 °C) under N2 and stirred (10 min). To the reaction mixture, 
4-fluorobenzyl chloride (70 µL, 0.484 mmol) was added dropwise by syringe which 
resulted in a clear yellow solution. The reaction mixture was stirred (1h), brought to room 
temperature and immediately quenched with saturated aqueous ammonium chloride 
solution (5 mL). The mixture was extracted with dichloromethane (3 x 10 mL) and the 
extracts were combined, dried over sodium sulfate, and concentrated. Purification of the 
crude residue was done by flash-column chromatography (hexanes/ethyl acetate, 4:1) to 
obtain pure 23 as colorless oil (86 mg, 60%); Rf = 0.55 (hexane/ethylacetate, 1:1); 1H NMR 
(500 MHz, CDCl3) δ 7.83 (d, J = 7.0 Hz, 1H), 7.54-7.51 (m, 1H), 7.45-7.41 (m, 2H), 7.22-
7.20 (m, 2H), 6.95-6.92 (m, 2H), 5.32-5.28 (m, 1H), 4.81 (d, J=16.5Hz, 1H), 4.51 (d, 
J=16.5Hz, 1H), 3.43-3.38 (m, 1H), 3.14-3.10(m, 1H), 1.43 (s, 9H) ppm; 13C NMR (125 
MHz, CDCl3) δ 169.9, 168.9, 162.7, 160.8, 141.6, 132.1 (d, J = 43.0 Hz), 131.5, 130.1 (d, 
J = 8.62 Hz), 127.9, 123.9, 122.7, 115.5 (d, J = 20.8 Hz), 82.39, 55.36, 47.38, 35.30, 27.96 
ppm; FT-IR (neat) 2979, 2932, 1732, 1671 cm -1; HRMS m/z calculated for C21H22FNO3
























tert-Butyl 3-(4-methoxyphenyl)-2-(1-oxoisoindolin-2-yl)propanoate. 24  
tert-butyl 2-(1-oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) was dissolved in 
freshly-distilled THF (3 mL) and lithium  hexamethyldisilazide (1.0M, 484 µL, 0.484 
mmol) was added in THF under N2  (-78 °C) by syringe. Stirring was continued (10 min) 
then 4- methoxybenzyl chloride (65.6µL, 0.484 mmol) was added to the reaction mixture 
dropwise by syringe which resulted in a yellow reaction mixture. The reaction mixture was 
stirred (1h) at -78 °C and then slowly warmed to room temperature followed by an 
immediate quench with saturated aqueous ammonium chloride (5 mL).  The reaction mass 
was extracted with dichloromethane (3 x 10 mL), the extracts were combined then dried 
over anhydrous sodium sulfate.  Concentration of the dried extracts provided a crude 
residue which was submitted to flash column chromatography (hexanes/ethyl acetate, 4:1). 
Pure 24 was obtained as a colorless oil (88 mg, 61%); Rf = 0.53 (toluene/ethyl acetate, 4:1); 
1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.0 Hz, 1H), 7.53-7.52 (m, 2H), 7.50-7.35 (m, 
9H), 7.27-6.79 (m, 4H), 5.33-5.29 (m, 1H), 4.63 (d, J=16.5Hz, 1H), 4,32 (d, J=16.5Hz, 
1H), 3.74-3.73 (s, 3H), 3.41-3.36 (m, 1H), 3.11-3.07 (m, 1H), 1.47-1.43 (m, 9H) ppm; 13C 
NMR (125 MHz, CDCl3) δ 170.2, 168.9, 158.4, 141.8, 132.1, 131.4, 129.6, 128.5, 127.8, 
123.8, 122.7, 114.02, 114.02, 82.2, 55.3, 55.2, 47.4, 35.2, 27.9 ppm; FT-IR (neat) 2977, 



























tert-Butyl 3-(naphthalen-1-yl)-2-(1-oxoisoindolin-2-yl)propanoate. 25 
 tert-Butyl 2-(1-oxoisoindolin-2-yl)acetate 15 (100 mg, 0.404 mmol) was dissolved in 
freshly-distilled THF (35 mL) and cooled to -5 °C N2. 1-Chloromethyl naphthalene (60 
µL, 0.404 mmol) was then added to the reaction mixture by syringe and stirring was 
continued (10 min). To the solution, lithium hexamethyldisilazide (1.0M, 606 µL, 0.606 
mmol) in THF was added dropwise by syringe. The reaction mixture was stirred (1 h) at -
5-0 °C, slowly brought to room temperature then quenched with saturated ammonium 
chloride solution (5 mL). The reaction mass was extracted with dichloromethane (3 x 10 
mL) and the extracts were combined, dried over sodium sulfate and concentrated. The 
residual crude solid mass  was submitted to flash column chromatography (hexanes/ethyl 
acetate, 5:1) to afford pure the pure 25 as a colorless oil (79 mg, 51%); Rf = 0.49 
(hexanes/ethyl acetate, 2:1); 1H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 13.5 Hz, 1H), 7.87-
7.85 (m, 2H), 7.73 (d, J = 7.5 Hz, 1H), 7.61-7.60 (m, 1H), 7.58-7.50 (m, 2H), 7.46-7.45 
(m, 1H), 7.43-7.40 (m, 1H), 7.36-7.32 (m, 2H), 5.48-5.45 (m, 1H), 4.62 (d, J=12.0Hz, 1H), 
4.43 (d, J=12.0Hz, 1H),  3.86-3.83 (m, 1H), 3.68-3.65 (m, 1H), 1.38 (s, 9H) ppm; 13C NMR 
(125 MHz, CDCl3) δ 170.1, 168.9, 141.8, 133.8, 132.6, 132.2, 131.8, 131.5, 128.9, 127.9, 
127.7, 126.5, 126.4, 125.7, 125.4, 123.8, 123.2, 122.8, 82.3, 77.3, 77.0, 76.8, 55.1, 47.7, 
33.1, 27.9 ppm; FT-IR (neat) 3055, 2980, 2938, 1734, 1690 cm-1; HRMS m/z calculated 

















Ethyl 3-(4,5-diphenyloxazol-2-yl)-2-(1-oxoisoindolin-2-yl)propanoate. 26  
Ethyl 2-(1-oxoisoindolin-2-yl)acetate 14 (100 mg, 0.456 mmol) was dissolved in freshly-
distilled THF(5.0 mL) and 2-(bromomethyl)-4,5-diphenyloxazole 38 (179 mg, 0.570 
mmol) was added at room temperature. Stirring was continued (10 min), then lithium 
hexamethyldisilazide (1.0M, 570 µL, 0.570 mmol) in THF was added dropwise by syringe 
to the reaction mixture which then turned yellow. The reaction mixture was stirred (16 h), 
quenched with saturated aqueous ammonium chloride solution (5 mL) and extracted with 
dichloromethane (3 x 10 mL). The organic extracts were combined, dried over anhydrous 
sodium sulfate and concentrated to give crude material which was submitted to gravity 
column chromatography (hexanes/ethyl acetate, 3:1). The pure 26 was obtained as a 
colorless oil (126 mg, 63%); Rf = 0.52 (hexanes/ethylacetate, 2:1); 1H NMR (500 MHz, 
CDCl3) δ 7.86 (d J = 7.5 Hz, 1H), 7.58-7.52 (m, 3H), 7.48-7.45 (m, 4H), 7.34-7.29 (m, 
6H), 5.63-5.60 (m, 1H), 4.69 (d, J=16.0Hz, 1H), 4.63 (d, J=16.)Hz, 1H),  4.26 (q, J = 7.0 
Hz, 2H), 3.70-3.66 (m, 1H), 3.60-3.55 (m, 1H), 1.27 (t, J = 7.0 Hz, 3H) ppm; 13C NMR 
(125 MHz, CDCl3) δ 169.7, 168.9, 159.0, 146.1, 141.9, 135.1, 132.2, 131.8, 131.7, 128.6, 
128.5, 128.1, 128.0, 127.8, 126.5, 124.0, 122.9, 61.9, 52.5, 48.0, 29.1, 14.1 ppm; FT-IR 





















General procedure for oxidation of the N-isoindolinone substrate, 15-26 to the N-
phthaloyl-protected amino acid derivatives 27-31, 34-35: 
To a clear solution of compounds 15-26 (1 equiv) in acetonitrile-H2O (9:1) was added 
Oxone® (5.0 equiv) and potassium bromide (0.5 equiv). The resulting reaction mixture was 
stired at 40-45 °C (16 h). After completion of reaction, solvent was concentrated and the 
residual material was partitioned between water (15 mL) and dichloromethane (20 mL). 
The organic layer was separated, dried over anhydrous magnesium sulfate and evaporated 
to obtain crude residue which was submitted to gravity-column chromatography using 
hexanes/ethyl acetate as an eluent to afford pure 27-31, 34-35. 
tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)acetate.44  27  
Off-white solid (44 mg, 88%); mp = 95-97 °C  [Lit. 96-96.8 °C] Rf = 0.38 (hexanes/ethyl 
acetate, 3:1); 1H NMR (400 MHz, CDCl3): δ 7.90-7.88 (m, 2H), 7.76-7.74 (m, 2H), 4.35 
(s, 2H), 1.48 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3): δ 167.6, 166.3, 134.1, 132.1, 
123.5, 82.8, 39.7, 27.9 ppm; FT-IR (neat): 2993, 1778, 1741, 1710, 1415, 1152 cm-1. 
Ethyl 2-(1,3-dioxoisoindolin-2-yl)propanoate.44 28  
Off-white solid (26 mg, 70%); mp = 60-62 °C [Lit. 61.5-62.5 °C]; Rf = 0.36 (hexanes/ethyl 
acetate, 3:1); 1H NMR (400 MHz, CDCl3): δ 7.86-7.84 (m, 2H), 7.73-7.71 (m, 2H), 4.94 
(q, J = 7.6 Hz, 1H), 4.21-4.16 (m, 2H), 1.67 (d, J = 7.2 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H) 
ppm; 13C NMR (125 MHz, CDCl3): δ 169.7, 167.5, 134.1, 131.9, 123.5, 61.8, 47.6, 15.3, 




















Ethyl 2-(1,3-dioxoisoindolin-2-yl)butanoate.44 29 
Colorless oil (12 mg, 76%); Rf = 0.44 (hexanes/ethyl acetate, 3:1); 1H NMR (400 MHz, 
CDCl3): δ 7.88-7.86 (m, 2H), 7.76-7.73 (m, 2H), 4.75 (dd, J = 5.6 Hz, 10.0 Hz, 1H), 4.20 
(q, J = 7.2 Hz, 2H), 2.31-2.22 (m, 2H), 1.22 (t, J = 7.2 Hz, 3H), 0.94 (t, J = 7.2 Hz, 3H) 
ppm; 13C NMR (125 MHz, CDCl3): δ169.3, 167.8, 134.1, 131.8, 123.5, 61.7, 53.8, 22.1, 


















































































































































tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)pentanoate. 30 
Colorless oil (25.6 mg, 98%); Rf = 0.39 (hexanes/ethyl acetate, 3:1); 1H NMR (400 MHz, 
CDCl3): δ 7.86-7.84 (m, 2H), 7.73-7.71 (m, 2H), 4.75 (dd, J = 4.8 Hz, 11.2 Hz, 1H), 2.27-
2.15 (m, 1H), 2.13-2.06 (m, 1H), 1.41 (s, 9H), 1.35-1.26 (m, 2H), 0.92 (t, J = 7.2 Hz, 3H) 
ppm; 13C NMR (125 MHz, CDCl3): δ 168.5, 167.9, 134.0, 131.9, 123.4, 82.3, 52.8, 30.6, 
27.9, 19.7, 13.4 ppm; FT-IR (neat): 2967, 1778, 1736, 1711, 1384, 1147 cm-1; HRMS 




















tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)hexanoate. 31 
Colorless oil (21 mg, 80%); Rf = 0.47 (ethyl hexanes/ethyl acetate, 3:1); 1H NMR (400 
MHz, CDCl3): δ 7.85-7.82 (m, 2H), 7.73-7.70 (m, 2H), 4.71 (dd, J = 4.4 Hz, 10.4 Hz, 1H), 
2.26-2.13 (m, 2H), 1.40 (s, 9H), 1.37-1.20 (m, 4H), 0.84 (t, J = 7.6 Hz, 3H) ppm; 13C NMR 
(125 MHz, CDCl3): δ 168.5, 167.9, 134.0, 131.9, 123.4, 82.3, 53.1, 28.6, 28.4, 27.9, 22.1, 
13.9 ppm; FT-IR (neat): 2960, 1778, 1737, 1712, 1385, 1150 cm-1; HRMS calcd. for 

















tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanoate.46 34 
Colorless oil (23 mg, 88%); Rf = 0.47 (hexanes/ethyl acetate, 3:1); 1H NMR (400 MHz, 
CDCl3): δ 7.76-7.74 (m, 2H), 7.66-7.64 (m, 2H), 7.16-7.10 (m, 5H), 5.05 (dd, J = 5.2 Hz, 
10.4 Hz, 1H), 3.53-3.49 (m, 2H), 1.43 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3): δ 167.8, 
167.6, 137.1, 133.9, 131.6, 128.8, 128.5, 126.7, 123.3, 82.8, 54.1, 34.7, 27.9 ppm; FT-IR 





















tert-Butyl 2-(1,3-dioxoisoindolin-2-yl)-3-(4-fluorophenyl)propanoate. 35  
Colorless oil (24 mg, 72%); Rf = 0.37 (hexanes/ethyl acetate, 3:1); 1H NMR (400 MHz, 
CDCl3): δ 7.77-7.75 (m, 2H), 7.68-7.66 (m, 2H), 7.09 (dd, J = 5.6 Hz, 8.4 Hz, 2H), 6.84 
(dd, J = 8.0 Hz, 8.8 Hz, 2H), 4.99 (dd, J = 6.4 Hz, 10.0 Hz, 1H), 3.48-3.46 (m, 2H), 1.43 
(s, 9H) ppm; 13C NMR (125 MHz, CDCl3): δ 167.6 (overlapped), 161.7 (d, J = 243.12 Hz), 
134.1, 132.8, 131.6, 130.3 (d, J = 7.6 Hz), 123.4, 115.4 (d, J = 21.0 Hz), 82.9, 54.1, 33.9, 
27.9 ppm; FT-IR (neat): 2980, 1776, 1737, 1714, 1386, 1154 cm-1; HRMS calcd. for 
























tert-Butyl 3-(2-bromonaphthalen-1-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoate. 37 
Colorless oil (17 mg, 80%); Rf = 0.54 (hexanes/ethyl acetate, 3:1); 1H NMR (400 MHz, 
CDCl3): δ 8.24-8.21 (m, 1H), 8.09-8.07 (m, 1H), 7.75-7.71 (m, 2H), 7.68-7.65 (m, 2H), 
7.58-7.51 (m, 4H), 7.08 (d, J = 7.2 Hz, 1H), 5.19 (dd, J = 4.8 Hz, 11.6 Hz, 1H), 4.06 (dd, 
J = 4.8 Hz, 14.8 Hz, 1H), 3.85 (dd, J = 11.6 Hz, 14.8 Hz, 1H), 1.45 (s, 9H) ppm; 13C NMR 
(125 MHz, CDCl3): δ 167.7, 167.5, 134.1, 133.5, 132.9, 132.1, 131.6, 129.3, 128.2, 127.5, 
127.2, 127.1, 123.6, 123.4, 122.3, 83.1, 53.3, 31.7, 27.9 ppm; FT-IR (neat): 2975, 1776, 




















Ethyl 4-amino-2-(1,3-dioxoisoindolin-2-yl)-4-oxobutanoate. 39 
Off-white solid (33 mg, 65%); mp =107-109 °C; Rf = 0.3 (chloroform/ethanol, 9:1); 1H 
NMR (400 MHz, CDCl3): δ 7.85-7.83 (m, 2H), 7.74-7.70 (m, 2H), 5.74 (s, 1H), 5.57 (s, 
1H), 5.44 (t, J = 8.0 Hz, 1H), 4.17 (q, J = 3.6 Hz, 2H), 3.23 (dd, J = 6.4 Hz, 15.6 Hz, 1H), 
3.02 (dd, J = 8.4 Hz, 15.6 Hz, 1H), 1.18 (t, J = 7.6 Hz, 3H) ppm; 13C NMR (125 MHz, 
CDCl3): δ 170.9, 168.7, 167.4, 134.3, 131.8, 123.6, 62.3, 48.7, 35.2, 14.0 ppm; FT-IR 
(neat): 3399, 3195, 2963, 1778, 1736, 1708, 1388, 1181 cm-1; HRMS calcd. for 


































tert-Butyl (tert-butoxycarbonyl)phenylalaninate.47 41  
To the solution of  N-phthaloyl 34 (50 mg, 0.14 mmol) in methanol (10 mL) was added 
hydrazine hydrate (70 µL, 10 equiv) followed by stirring (16 h) at room temperature. After 
completion of reaction as confirmed by TLC (hexanes/ethyl acetate, 8:2), the reaction 
mixture was concentrated to give a white residue.   Dichloromethane (15 mL) was added 
to the residue followed by stirring (15 min) at room temperature. Filtration and 
concentration of the filtrate gave a colorless oily residue (31 mg). The residue was 
dissolved in 1,4-dioxane (10 mL) and to the solution was added sodium bicarbonate (14.1 
mg, 0.14 mmol) followed by tert-butyl dicarbonate (31.0 mg, 0.14 mmol) at room 
temperature. The resulting reaction mixture was stirred (16 h) at room temperature. After 
completion of reaction as confirmed by TLC (hexane/ethyl acetate, 8:2), the solvent was 
evaporated, and the residue was partitioned between dichloromethane (10 mL) and water 
(10 mL). The organic layer was separated, dried over anhydrous sodium sulfate and 
evaporated to obtain crude a residue which was submitted to gravity-column 
chromatography (hexanes/ethyl acetate, 8:2) to afford pure 41 as a colorless oil (37 mg, 
81%); Rf = 0.56 (hexanes/ethyl acetate, 7.5:2.5); 1H NMR (400 MHz, CDCl3): δ 7.28-7.19 
(m, 3H), 7.16-7.14 (m, 2H), 4.97 (d, J = 8.4 Hz, NH), 4.43 (dd, J = 6.4 Hz, 14.0 Hz), 3.03 
(d, J = 6.0 Hz, 2H), 1.40 (s, 9 H), 1.38 (s, 9H) ppm; FT-IR (neat): 2978, 2933, 1713, 1496, 
















PART C. DAST MEDIATED ALKOXYLATION
193 
Introduction 
The isoindolinone is a functional heterocycle found in medicinal chemistry and 
observed in natural products.1-3 On the isoindolinone core, substitution with a carbon or 
heteroatom framework is observed on the benzene ring, the heterocyclic nitrogen atom, 
and/or especially on the benzylic methylene in many biologically active compounds. The 
isoindolinone core as an alkoxylated derivative is apparent in a range of active compounds 
such as antivirals (Figure 22a),4 inhibitors of protein-protein interaction (Figure 22b),5 
muscarinic receptor ligands (Figure 22c),6-7 cytotoxic and cytostatic agents.8 While 
examining investigative studies for chiral auxiliaries that utilized substituted 
isoindolinones, a mild bond formation was examined on the benzylic position of chiral N- 
substituted isoindolinones was examined. There have been multiple approaches that utilize 
a hydroxylactam derived from an isoindolinone to undergo bond formation from the 
generation of an acyliminium ion through acid catalysis or with a Lewis acid in which the 
Figure 22. Alkoxyisoindolinone products that are active as a.) antiviral agent, b.) protein-
protein interaction inhibitor, and c.)  muscarinic receptor ligand. 
(a) 1 (b)    2 
(c)    3 
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acyliminium ion can easily undergo a nucleophilic reaction with alcohols and thiols.9-13 
Outside of the acyliminium ion approach, hydroxylactam can undergo chlorination to form 
a stronger electrophile for subsequent reactions involving an anionic nucleophile.5,6 Both 
of these approaches successfully utilize the hydroxylactam which is easily obtained from 
the reduction of the corresponding phthalimides by sodium borohydride, 
diisobutylaluminum hydride, or aluminum amalgam.14 The reaction of an 
hydroxyisoindolinone with an alcohol is a direct approach to synthesize functional 
alkoxyisoindolinones and is most commonly done through strong acid or metal catalysis.15-
18 Both of these sets of reaction conditions readily synthesize alkoxyisoindolinones but 
sometimes occur under harsh conditions.  
Diethylaminosulfur trifluoride (DAST) is a mild fluorinating agent which has been 
utilized to prepare fluorinated analogues from a range of medicinal compounds and natural 
products.19 Fluorination with DAST is done on both alcohols and aldehydes to yield 
monofluorinated analogues from alcohol or gem-difluorinated analogues from aldehyde 
and has been the major topic of interest for the use of DAST. The mechanism for 
fluorination by DAST has two possibilities (Scheme 18)20,21. The first is direct fluorine 
nucleophile displacement,22 and the second relies on the formation of a carbocation where 
fluorine is a nucleophile.23 In fluorination reactions of chiral stereogenic centers bearing 
an alcohol, DAST promotes stereoinversion reactions on a range of compounds containing 
a chiral alcohol. With the chiral alcohols, the mechanism involves DAST coordinating with 
a chiral alcohol and disposition of the DAST-alcohol complex is done by a fluorine 
nucleophile and has been reported to be completed stereoselectively.   
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Scheme 18. Plausible DAST mediated mechanism through a.) nucleophile displacement 
and b.) through carbocation formation 
In some of the early reports of using DAST, an ether formation was reported by 
Johnson in 1982 (Scheme 19).24 Johnson was able to utilize DAST to form an ether bond 
between two diarylcarbinols by stirring them together with the addition of DAST. More 
recently groups have reported ether formation as a minor pathway to substantial by-product 
towards expected fluorination.25,26 It is likely that ether formation competes with 
fluorination in cases where formation of a carbocation is highly stabilized, and this is seen 
Scheme 19. DAST mediated ether formation presented by Johnson. 
in the cases reported with benzyl alcohols that have the additional stability of a carbocation 
intermediate. Alcohols will readily undergo fluorination with DAST and preclude ether 
formation, likely due to the stability and reactivity of the alcohol. 
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We report herein that hydroxylactam used with DAST and the addition of a range 
of alcohols leads to a new ether bond in generation of alkoxylactams 
(alkoxyisoindolinones) in good to excellent yields (Scheme 20). The yields obtained with 
Scheme 20. DAST mediated alkoxylation. 
an acid-catalyzed ether formation when using p-toluenesulfonic acid or camphorsulfonic 
acids are greater than or comparable to DAST mediation. Under both DAST and acid 
catalysis of chiral N-phenethyl hydroxylactams, the reactions generate alkosyisoindolinone 
products as a diastereomeric mixture. Due to the chiral N-phenethy group, benzylic 
alkoxylated products generates an unequal ratio of diastereomeric products from the 
racemic hydroxyl starting material.27  
Results and Discussions 
Preliminary studies were to investigate the effectiveness of alkoxylation with a 3-
hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one 7 as a starting material. The described 
route to the synthesis of alkoxyisoindolinones utilizes the diastereomeric mixture of 7 
(Scheme 21).28,29 Though a-hydroxyisoindolinone is not commercially-available, a two-
step synthesis is accomplished by reacting commercially-available phthalic anhydride with 
(S)-1-phenylethan-1-amine neat at 90 °C overnight, followed by the final closure of the 
benzamidic acid by the addition of acetic acid and increase of the temperature to 130 ºC 
(16 h). Purification of chiral (S)-2-(1-phenylethyl)isoindoline-1,3-dione is achieved 
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through gravity column chromatography yielding white crystals. Hydroxylactam 7 is 
prepared by regioselective reduction of chiral (S)-2-(1-phenylethyl)isoindoline-1,3-dione 
6 utilizing less than one equivalent of sodium borohydride in methanol at -5 to 0 °C for 30 
minutes to yield 3-hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one 7. Under these 
conditions, 7 undergoes a workup and is purified by column chromatography to provide a 
mixture of diastereomers.  
Scheme 21. Preparation of Hydroxyisoindolinone. Reagents/Conditions: (a) (i) Neat/90 
°C/20 h, (ii) Ac2O/110 °C/16 h; (b) NaBH4/MeOH/2 h 
A variety of alcohols were subjected to an alkoxylation reaction using DAST in the 
novel application. This approach takes advantage of the ability of diethylaminosulfur 
trifluoride to complex with hydroxyl groups and generate an acyliminium ion. A wide array 
of alcohols were utilized to probe the scope of the reaction. When determining the scope 
of the reaction, alkoxylation of 7 was performed initially by complexation of the 
diethylaminosulfur trifluoride with the starting material under an inert atmosphere, N2 (g), 
at -15 °C and allowed to stir overnight to room temperature. Diethylaminosulfur trifluoride 
can yield a stable complex with the hydroxyl of the 3-hydroxy-2-((S)-1-
phenylethyl)isoindolin-1-one to generate either a DAST-hydroxyl complex or a stabilized 
acyliminium ion, with both being plausible intermediates when utilizing DAST for 
fluorination. The alcohol is added dropwise to the reaction mixture and allowed to stir at 
room temperature until completion, (4-8 hours) and monitored by TLC. The 
  b. a. i. 
ii. 
4 5 6 7 
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alkoxyisoindolinones, 8-17 are synthesized in moderate to good yields (60-91%) utilizing 
diethylaminosulfur trifluoride (Table 6). All alkoxylated products are purified with flash 
column chromatography and contain a mixture of inseparable diastereomers in a ratio 
(55:45 to 65:35) determined by H1 NMR. The most selective alkoxyisoindolinone 
synthesized was seen with trichloroethanol having an 80:20 diastereomeric ratio. The range 
of diastereomers synthesized follows a loose trend in which the least selective alcohol is 
the benzyl alcohols, followed by the aliphatic alcohols, and lastly the most selective alcohol 
is trichloroethanol. The trend suggests that the benzyl alcohols are less selective and is 
likely due to the benzyl derivatives being stabilized through p-p interactions when the 
alcohol is approaching from the more hindered side.  
Table 6. Products from hydroxyisoindolinone and alcohol with diethylaminosulfur 
trifluoride. 
Product/Yield Alcohol  Ratio Product/Yield Alcohol Ratio 
8 (89%) 
10 eq 60:40 
14 (85%) 
5 eq 80:20 
  a. 




10 eq 60:40 
14 (71%) 
5 eq 65:35 
10 (80%) 
5 eq 55:45 
15 (77%) 
5 eq 65:35 
11 (91%) 
5 eq 65:35 
16 (83%) 
5 eq 65:45 
12 (60%) 
5 eq 55:45 
17 (79%) 
5 eq 60:40 
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13 (71%) 
5 eq 65:35 
Reagents/Conditions: (a) DAST/DCM/0 °C/2-6 hr. (b) ROH/0 °C/2-6 hr. 
In proposing a likely mechanism, the pure diastereomer, (S)-3-hydroxy-2-((S)-1-
phenylethyl)isoindolin-1-one is utilized in determining whether the nucleophilic attack of 
the alcohol is either an SN1 or SN2 mechanism. The pure diastereomer was selectively 
crystallized in 9:1 diethyl ether:hexane as demonstrated by Daich et al10 The pure 
diastereomer was subjected to the reaction conditions with diethylaminosulfur trifluoride 
as previously described. After stirring overnight, an addition of b-phenethanol (3 equiv.) 
was added and allowed to stir until completion through monitoring with TLC. Knowing 
that DAST can undergo fluorination by direct nucleophilic substitution, the pure 
diastereomer was utilized as the starting reagent as a means of analyzing whether an N-
acyliminium ion was generated and alcohol attack (SN1) or if direct displacement of the 
alcohol-DAST complex occurred (SN2). Thus, when envisioning a direct nucleophilic 
attack with the b-phenethanol present, a complexation between the DAST and the free 
alcohol can be proposed (Scheme 22). Much like how DAST undergoes fluorination, it 
was expected that the free alcohol would displace the DAST-hydroxyl complex on the 
molecule. This occurrence would have resulted in direct stereoconversion on the hydroxyl 
carbon and would be identifiable by H1 NMR.30,31 Upon purification of the product that 
utilized pure 
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Scheme 22. Proposed SN2-like reaction mechanism through a DAST complexation. 
diastereomer (S)-3-hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one and b-phenethanol, a 
diastereoisomeric mixture (60:40) was observed. The lack of a diastereomer in a high 
percentage suggest that the DAST-hydroxyl complex is at least not the predominant 
pathway in synthesizing alkoxyisoindolinone derivatives. This observation likely suggests 
deoxygenation occurs and therefore, a stable N-acyliminium ion which is generated and is 
subsequently alkoxylated.  
While there is no evidence of direct nucleophilic attack through the DAST-
hydroxyl complex, a mixture of major and minor diastereomers are formed, which can be 
predicted to be a result of the generation of an N-acyliminium ion (SN1). This pathway 
utilizes a Felkin-Ahn model7 that accurately depicts the reasoning for an unequal 
18 
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distribution of diastereomers observed (Scheme 23). The DAST complexes to the free 
hydroxyl of the pure enantiomer and subsequently is able to act as a stable leaving group 
and generate the highly stabilized N-acyliminium ion. The stabilized N-acyliminium ion 
allows for a non-stereoselective alkoxylation due to the chiral N-phenethyl handle. Chiral 
induction is observed in the synthesized product where a major diastereomer is favored.  
Scheme 23. Proposed mechanism utilizing DAST to generate an N-acyliminium ion. 
18 
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The induction is rationalized through the Felkin-Ahn model and one enantiomer will be 
favored strictly due to the accessibility of a nucleophilic addition taking place. The addition 
of the alcohol must come in from either the top face or the bottom face. The approach from 
either side contains a difference in gauche interactions due to the chiral handle, N-
phenethyl. Unequal distribution is likely due to the generation of the N-acyliminium ion 
formation, in which the reaction proceeds through a SN1 mechanism.    
To confirm that the DAST mechanism proceeds solely through a generated 
acyliminium ion, an acid catalyzed reaction was used to validate the postulated mechanism. 
Alkoxylation of the hydroxylactam was completed by utilizing an acid catalyzed reaction. 
Camphorsulfonic acid (CSA) was used as the catalyst and reacted with select alcohols used 
from the DAST reaction. The aforementioned alkoxyisoindolinones 15-17 were then 
synthesized with a catalytic amount of CSA and were prepared in moderate yields 75 - 
83% (Table 7). Nearly identical diastereomeric ratios are seen between the DAST and CSA 
mediated alkoxylation reactions. Thus, confirming the DAST mediated reaction goes 
through the stable N-acyliminium ion formation. 
The use of diethylaminosulfur trifluoride and the use of camphorsulfonic acid both 
resulted in a-amidoalkoxylation through the generation of a stable N-acyliminium ion. 
Both reaction conditions generated a mixture of diastereomers in comparable ratios that 
are inseparable by column chromatography at good to modest yields. The advantages of 
using camphorsulfonic acid are the catalytic amount and the ability to generate the N-
acyliminium ion in the presence of the alcohol co-reactant. While advantages of utilizing 
camphorsulfonic acid exist, DAST can be used in the presence of acid sensitive functional 
groups within molecules. DAST also has been previously reported to solely induce 
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alkoxylation and generally provided a higher yield than camphorsulfonic acid from 
comparing the alkoxylated analogues.  
Table 7. Products from hydroxyisoindolinone and alcohol with camphorsulfonic acid.  







Reagents/Conditions: (a) CSA/DCM/0 °C/2-6 hr. 
While alkoxylation with the use of DAST is unable to generate a stereospecific 
reaction, a route to isolate the pure enantiomer 18 from fractional crystallization for an 
esterification reaction was accomplished (Scheme 24). The esterification reaction was 
accomplished under slightly basic conditions (pyridine, 100 µL) and with acetic anhydride 
  a. 
7 15-17 
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(50 µL). The acetylation reaction yielded the diastereomerically pure product (S)-3-oxo-2-
((S)-1-phenylethyl)isoindolin-1-yl acetate 20 with an optical rotation of  [a]D +36° (c =  
0.9 M in CHCl3). The reaction performed had a moderate yield (56%). It was demonstrated 
that the pure enantiomer is capable of undergoing chemical reactions that will maintain the 
chiral center without epimerizing to yield a diastereomeric ratio.  
Scheme 24.  Preparation of (S)-3-oxo-2-((S)-1-phenylethyl)isoindolin-1-yl acetate. (a) 
Pyridine/RT/24 h (56% yield) 
Envisioning a reaction by which an alkoxide is generated and subsequently attacks 
an alkyl halide would allow for desired products to be diastereomerically pure. Conversely, 
the generation of the alkoxide from the diastereochemically-pure compound with sodium 
hydride (NaH) in THF and the addition of benzyl bromide did not generate the desired 
benzyl alkoxyisoindolinone. A racemic mixture of hydroxylactams was the only observed 
product from the attempted alkoxylation reaction. This is likely due to the formation of an 
aldemide under highly basic conditions causing epimerization of the hydroxyl functional 
group.   
In determining the stability of the stereocenter of the hydroxyl carbon, an 
epimerization study on the hydroxyl carbon of the enantiomerically pure compound was 
noted in an H1 NMR experiment utilizing a slightly stronger base, triethylamine. The 
epimerization study was performed by adding (S)-3-hydroxy-2-((S)-1-
phenylethyl)isoindolin-1-one 18 (10 mg) in CDCl3 (1 mL) to be analyzed in an H1 NMR 
  a. 
18 19 20 
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tube. Triethylamine was added (5 equiv, 27 µL) to the pure hydroxylactam and 
epimerization was seen to occur over the course of 24 hours. The doublet (d 1.84, 3H) 
corresponding to the phenethyl chiral handle was the standard in determining the percent 
of epimerization occurring (Figure 23a). Over the first 3 hours no quantifiable change had 
been observed, but after 24 hours, (Figure 23b) 18% conversion was observed of one 
enantiomer to a mixture of diastereomers.  
Figure 23. Epimerization study converting the starting pure enantiomer (left) with 5 
equivalents of triethylamine to a mixture of diastereomers (right). 
In tandem, the acylation and the epimerization studies suggest that a weak base 
could allow alkoxylation to occur while retaining its stereocenter, but the chosen base must 
also be weak enough to not cause epimerization. All structures of the products synthesized 
were confirmed by 1H and 13C NMR including elemental analysis.  
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Conclusions 
We have demonstrated an efficient route to 3-alkoxyisoindolinones from an 
hydroxylactam mediated with a fluorinating reagent DAST in place of a strong acid. 
Synthesis of the alkoxyisoindolinone is mediated by an acyliminium ion that DAST 
generates through complexation with hydroxyl of the hydroxylactam. The chiral 
phenethylamine has minor chiral induction and dependent on the alcohol attaching to the 
acyliminium a minor and major product is observable and the diastereomeric ratio can be 
quantified by 1H NMR. (For publication see Appendices p. 281) 
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Experimental 
General. Solvents and reagents were ACS grade and were used as commercially supplied. 
Analytical thin-layer chromatography (TLC) utilized 0.25 mm pre-cut glass-backed plates 
(Merck, Silica Gel 60 F254). Thin-layer chromatograms were visualized during 
chromatographic and extraction runs by rapidly dipping the plates in 
anisaldehyde/ethanol/sulfuric acid stain or phosphomolybdic acid/ ethanol stain and 
heating (hot plate). Gravity-column chromatography was carried out using silica gel 60 (E. 
Merck 7734, 70-230 mesh). Nuclear magnetic resonance (1H and l3C NMR) spectra were 
recorded with Varian VNMRS 400, 500, or 700 MHz instruments using CDCl3 as a solvent 
and TMS as internal standard. Infrared spectra (FTIR) were recorded with a PerkinElmer 
Spectrum 100 instrument and spectral values are reported as cm-1.  
 (S)-2-(1-phenylethyl)isoindoline-1,3-dione: 6 
Phthalic anhydride (2.44g, 16.5 mmol) was added to (S)-phenethylamine (2.00g, 16.5 
mmol) neat and allowed to stir 16 hr at 90 ºC. Acetic anhydride (15 mL) was added and 
allowed to stir 48 hr at 110 ºC. The crude reaction mixture was directly submitted to 
gravity-column chromatography hexane:ethyl acetate(4:1) to afford pure 6 as white 
crystalline product (2.86g, 65%). Optical rotation was [a]D -62° (c = 0.5 M in CHCl3).26   
3-hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one: 7 
(S)-2-(1-phenylethyl)isoindoline-1,3-dione (500mg, 1.99mmol) was dissolved in methanol 
(20mL) at -5-0 ºC. Sodium borohydride (225.8 mg, 5.97 mmol) was added slowly to the 
solution and allowed to stir for 30 minutes. Reaction was quenched using aqueous 10% 
hydrochloric acid (1 mL). Reaction was concentrated then washed with sodium bicarbonate 
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(4 mL) and extracted with dichloromethane (3x 10 mL). Solution was concentrated to yield 
7 as white crystals (460 mg, 92%).26 
General procedure for synthesis of 3-alkoxy-2-((S)-1-phenylethyl)isoindolin-1-one: 7-
17 
3-hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one (150 mg, 0.592 mmol)a or (100mg, 0.395 
mmol)b was dissolved in dichloromethane (3.0 mL) under inert atmosphere (N2) while 
stirring followed by the addition diethylaminosulfurtrifluoride (DAST,  240 µL, 1.776 
mmol, 3 eq). Stirring was continued overnight (16 hr) and alcohol was added and stirred 
until the reaction was complete as indicated by TLC (4-8 hr). The crude reaction mixture 
was directly submitted to gravity-column chromatography.  
For compounds 7-17 either a or b is used to denote the scale of the reaction.  
General procedure for synthesis of 3-alkoxy-2-((S)-phenylethyl)isoindolin-1-one: 15-
17 
3-hydroxy-2-((S)-1-phenylethyl)isoindolin-1-one (100mg, 0.395 mmol) was dissolved in 
dichloromethane (3.0 mL) with alcohol (1.2 eq) in the presence of camphorsulfonic 
acid(20% eq). Stirring was continued overnight (4-6 hr) until the reaction was complete as 
indicated by TLC (4-8 hr). The crude reaction mixture was directly submitted to gravity-
column chromatography.  
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3-isopropoxy-2-((S)-1-phenylethyl)isoindolin-1-one.a 7 
 Colorless oil (158 mg, 89%); Rf = 0.44 (hexane/ethyl acetate, 4:1); IR 3029, 2976, 2927, 
2886, 1698 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.81-7.84 (m, 1H), 7.25-7.55 (m, 8H), 5.68 (q, J = 7.0 Hz, 1H), 5.53 
(s, 1H), 3.66-3.70 (m, 1H), 1.83 (d, J = 6.5 Hz, 3H), 1.18 (d, J = 6.0 Hz, 3H), 1.05 (d, J = 
6.0 Hz, 3H)  1H NMR (500 MHz, CDCl3, minor) d 7.81-7.84 (m, 1H), 7.25-7.55 (m, 8H), 
5.76 (s, 1H), 5.15 (q, J = 7.0 Hz, 1H), 3.66-3.70 (m, 1H), 1.98 (d, J = 7.5 Hz, 3H), 1.15 (d, 
J = 6.5 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H). 13C NMR (500 MHz, CDCl3) d 168.0, 127.7, 
143.0, 142.3, 140.5, 132.9, 132.1, 131.9, 131.8, 129.7, 129.5, 128.5, 128.4, 128.2, 127.5, 
127.2, 126.6, 123.5, 123.4, 123.3, 85.9 (major), 85.6 (minor), 69.4, 68.7, 52.0, 50.2, 23.9, 
23.7, 23.2, 3.0, 18.9, 18.9. HRMS (FTMS + p ESI) m/z [M + Na]+; calculated for 












Colorless oil (167 mg, 88%); Rf = 0.48 (hexane/ethyl acetate, 4:1);  IR 3030, 2999, 2959, 
2871, 1697 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.81-7.84 (m, 1H), 7.25-7.55 (m, 8H), 5.68 (q, J = 7.5 Hz, 1H), 5.54 
(s, 1H), 3.91-3.93 (m, 1H), 1.81 (d, J = 7.0 Hz, 3H), 1.31-1.74 (m, 8H). 1H NMR (500 
MHz, CDCl3, minor) d 7.81-7.84 (m, 1H), 7.25-7.55 (m, 8H), 5.81 (s, 1H), 5.17 (q, J = 7.0 
Hz, 1H), 3.78-3.80 (m, 1H), 1.96 (d, J = 7.0 Hz, 3H) 1.31-1.74 (m, 8H). C13 NMR (500 
MHz, CDCl3) d 168.1, 167.8, 142.6, 142.2, 140.5, 132.9, 132.3, 131.7, 129.7, 129.6, 128.6, 
128.4, 127.7, 127.6, 127.3, 127.2, 126.6, 123.8, 123.8, 123.5, 123.3, 86.0 (major), 85.8 
(minor), 51.7, 50.3, 33.7, 33.5, 33.4, 33.3, 23.6, 23.4, 23.2, 18.7, 18.3. HRMS (FTMS + p 










































































































































Colorless oil (108 mg, 80%); Rf = 0.47 (hexane/ethyl acetate, 4:1) IR 3031, 2928, 2886, 
2875, 1698 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.88-7.89 (m, 1H), 7.21-7.60 (m, 12H), 6.92-6.94 (m, 1H), 5.79 (s, 
1H), 5.73 (q, J = 7.0 Hz, 1H), 4.32 (d, J = 11.0 Hz, 1H), 3.97 (d, J = 11.0 Hz, 1H), 1.84 (d, 
J = 7.0 Hz, 3H). 1H NMR (500 MHz, CDCl3, minor) d 7.88-7.89 (m, 1H), 7.21-7.60 (m, 
12H), 6.92-6.94 (m, 1H), 6.19 (s, 1H), 5.47 (q, J = 7.5 Hz, 1H), 3.73 (d, J = 11.0 Hz, 1H), 
3.62 (d, J = 11.0 Hz, 1H), 1.91 (d, J = 7.0 Hz, 3H). C13 NMR (500 MHz, CDCl3) d 167.8, 
141.7, 141.0, 140.7, 140.3, 137.4, 137.2, 133.1, 132.6, 132.1, 130.0, 129.9, 128.7, 128.4, 
127.8, 127.7, 127.6, 127.5, 123.7, 123.6, 123.4, 110.0, 85.8 (major), 85.6 (minor), 64.1, 
63.9, 50.7, 50.6, 18.1, 17.5. HRMS (FTMS + p ESI) m/z [M + Na]+; calculated for 












Colorless oil (193 mg, 91%); Rf = 0.67 (hexane/ethyl acetate, 4:1); IR 3066, 3028, 2937, 
2875, 1698 cm -1 A mixture of two inseparable diastereomers (dr = 3:1.6) 1H NMR (500 
MHz, CDCl3, major) d 7.81-7.82 (m, 1H), 7.11-7.59 (m, 12H), 6.94 (d, J = 8.0 Hz, 1H), 
5.64 (q, J = 7.0 Hz, 1H), 5.61 (s, 1H) 3.47 (dd, J = 16.0, 7.0 Hz, 1H), 3.09 (dd, J = 16.0, 
7.0 Hz, 1H), 2.79-2.88 (m, 2H), 1.72 (d, J = 7.5 Hz, 3H). 1H NMR (500 MHz, CDCl3, 
minor) d7.81-7.82 (m, 1H), 7.11-7.59 (m, 13H), 6.03 (s, 1H), 5.35 (q, J = 7.5 Hz, 1H), 
2,79-2.88 (m, 2H) 2.40-2.46 (m, 1H), 2.28-2.32(m, 1H), 1.85 (d, J = 7.0 Hz, 3H). 13C NMR 
(125 MHz, CDCl3) d 167.7, 141.0, 140,4 138.40, 132.6, 131.9, 129.8, 129.7, 129.0, 128.9, 
128.6, 128.4, 128.2, 127.8, 127.7, 127.6, 127.4, 126.4, 126.3, 123.6, 123.5, 123.2, 85.7 
(major), 85.3 (minor), 62.9, 62.5, 50.7, 50.3, 26.1, 25.5, 17.9, 17.4.  HRMS (FTMS + p 












Colorless oil (88 mg, 60%); Rf = 0.37 (hexane/ethyl acetate, 4:1) IR 3063, 2989, 2941, 
2843, 1702 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.87-7.88 (m, 1H), 7.14-7.60 (m, 8H), 6.77-6.83 (m, 3H), 6.50-6.53 
(m, 1H), 5.79 (s, 1H) 5.73 (q, J = 8.0 Hz, 1H), 4.29 (d, J = 11.5 Hz, 1H), 3.95 (d, J = 11.5 
Hz, 1H), 3.81 (s, 3H), 1.84 (d, J = 7.0 Hz, 3H). 1H NMR (500 MHz, CDCl3, minor) d 7.87-
7.88 (m, 1H), 7.14-7.60 (m, 8H), 6.77-6.83 (m, 3H), 6.50-6.53 (m, 1H), 6.19 (s, 1H), 5.47 
(q, J = 7.0 Hz, 1H), 3.77 (s, 3H), 3.69 (d, J = 11.0 Hz, 1H), 3.57 (d, J = 11.0 Hz, 1H), 1.91 
(d, J = 7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3) d 167.5, 159.7, 141.7, 141.0, 140.7, 140.3, 
139.0, 138.8, 133.1, 132.6, 132.1 123.0, 129.5, 129.2, 128.7, 128.4, 127.8, 127.7, 127.5, 
123.7, 123.6, 123.4, 120.0, 119.8, 113.2, 113.1, 113.0, 85.8 (major), 85.6 (minor), 63.9, 
63.8, 55.2, 30.7, 18.1, 17.5.  HRMS (FTMS + p ESI) m/z [M + Na]+; calculated for 























Colorless oil (118 mg, 71%); Rf = 0.29 (hexane/ethyl acetate, 9:1) IR 3077, 3035, 2984, 
2937, 1686 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.88-7.90 (m, 1H), 7.10-7.56 (m, 12H), 5.89 (s, 1H), 5.75 (q, J = 
7.0 Hz, 1H), 4.40 (d, J = 12.0 Hz, 1H), 4.07 (d, J = 12.5 Hz, 1H), 1.83 (d, J = 7.5 Hz, 3H). 
1H NMR (500 MHz, CDCl3, minor) d 7.88-7.90 (m, 1H), 7.10- 7.56 (m, 11H) 5.47 (q, J = 
7.0 Hz, 1H), 4.06 (d, J = 12.5 Hz, 1H), 3.87 (d, J = 12.5 Hz, 1H), 1.92 (d, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3) d 167.9, 167.8, 141.6, 140.7, 140.4, 140.3, 136.9, 136.7, 
132.9, 132.5, 132.3, 132.2, 132.1, 130.1, 130.0, 129.4, 129.2, 129.1, 128.9, 128.7, 128.4, 
127.8, 127.5, 127.4, 127.3, 127.1, 123.8, 123.6, 123.5, 123.4, 122.8, 122.7, 85.7 (major), 
85.5 (minor), 63.7, 63.6, 50.7, 50.6, 18.1, 17.6. HRMS (FTMS + p ESI) m/z [M + Na]+; 















Colorless oil (129 mg, 85%); Rf = 0.47 (hexane/ethyl acetate, 2:1) IR 3046, 3035, 2980, 
2936, 1677 cm -1 A mixture of two inseparable diastereomers (dr = 3:1) 1H NMR (500 
MHz, CDCl3, major) d 7.87-7.88 (m, 1H), 7.27-7.62 (m, 8H), 5.88 (s, 1H), 5.72 (q, J = 7.5 
Hz, 1H), 3.94 (d, J = 10.5 Hz, 1H), 3.44 (d, J = 10.5 Hz, 1H), 1.89 (d, J = 7.0 Hz, 3H). 1H 
NMR (500 MHz, CDCl3, minor) d 7.87-7.88 (m, 1H), 7.27-7.62 (m, 8H), 6.24 (s, 1H), 5.48 
(q, J = 7.5 Hz, 1H), 3.18 (d, J = 10.5 Hz, 1H), 3.08 (d, J = 10.5 Hz, 1H), 1.93 (d, J = 7.0 
Hz, 3H). 13C NMR (125 MHz, CDCl3) d 167.6, 141.1, 139.9, 139.5, 139.1, 132.9, 132.7, 
132.5 130.6, 130.5, 128.8, 128.7, 128.0, 127.7, 127.6, 124.0, 123.9, 123.7, 95.9, 85.7 
(major), 85.5 (minor), 74.2, 73.9, 50.9, 18.0, 17.4. HRMS (FTMS + p ESI) m/z [M + Na]+; 





















Colorless oil (81 mg, 70%); Rf = 0.45 (hexane/ethyl acetate, 9:1) IR 3041, 3010, 2976, 
2942, 1700 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.84-7.85 (m, 1H), 7.24-7.58 (m, 8H), 5.80-5.84 (m, 1H), 5.70 (q, 
J = 7.5 Hz, 1H), 5.67 (s, 1H) 4.94-4.99 (m, 1H), 3.54 (dd, J = 11.0, 5.5 Hz, 1H), 3.45 (dd, 
J = 11.0, 5.5 Hz, 1H), 1.80 (d, J = 7.0 Hz, 3H). 1H NMR (500 MHz, CDCl3, minor) d 7.84-
7.85 (m, 1H), 7.24-7.58 (m, 8H), 6.09 (s, 1H), 5.44 (q, J = 7.0 Hz, 1H), 5.37-5.40 (m, 1H), 
5.23 (d, J=7.0 Hz, 2H), 4.94-4.99 (m, 1H), 3.20 (dd, J = 13.5, 7.5 Hz, 1H), 3.10 (dd, J = 
13.5, 7.5 Hz, 1H), 1.89 (d, J = 7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3) d 167.7, 167.6, 
141.7, 140.9, 140.6, 140.2, 133.8, 133.6, 133.0, 132.6, 132.0, 129.9, 129.8, 128.6, 128.4, 
128.2, 127.9, 127.8, 127.7, 127.4, 126.6, 123.7, 123.5, 123.3, 117.1, 117.0, 85.5 (major), 
85.3 (minor), 62.9, 62.8, 50.5, 50.4, 17.9, 17.4. HRMS (FTMS + p ESI) m/z [M + Na]+; 












Colorless oil (103 mg, 80%); Rf = 0.19 (hexane/ethyl acetate, 2:1); IR 3405 br, 2940, 2874, 
2836, 1683 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 1H NMR (500 
MHz, CDCl3, major) d 7.81-7.83 (m, 1H), 7.22-7.24 (m, 8H), 5.65 (q, J = 6.5 Hz, 1H), 5.62 
(s, 1H), 3.86-3.89 (m, 1H), 3.60-3.71 (m, 3H), 3.41-3.46 (m, 1H), 3.28-3.30 (m, 1H) 2.87-
2.89 (m, 1H), 1.57-2.0 (4H), 1.23-1.34 (m, 2H). 1H NMR (500 MHz, CDCl3, minor) d 7.81-
7.83 (m, 1H), 7.22-7.24 (m, 8H), 6.03 (s, 1H), 5.43 (q, J = 6.0 Hz, 1H), 3.60-3.71 (m, 3H), 
3.41-3.46 (m, 1H) 2.60-2.68 (m, 2H), 1.57-2.0 (m, 4H), 1.15-1.18 (m, 1H), 1.09-1.10 (m, 
1H). 13C NMR (125 MHz, CDCl3) d 167.8, 141.8, 141.3, 140.9, 140.5, 133.1, 132.7, 132.2, 
130.0, 129.9, 128.8, 128.5, 127.9, 127.8, 127.5, 123.8, 123.7, 123.3, 85.8 (major), 85.4 
(minor), 62.7, 62.6, 61.9, 61.7, 50.8, 50.3, 29.7, 29.5, 26.2, 25.7, 18.1, 17.5. HRMS (FTMS 




































































































































































Colorless oil (101 mg, 75%); Rf = 0.25 (hexane/ethyl acetate, 2:1); IR 3449 br, 3061, 2973, 
2870, 1686 cm -1 A mixture of two inseparable diastereomers (dr = 3:1.6) 1H NMR (500 
MHz, CDCl3, major) d 7.84-7.85 (m, 1H), 7.27-7.58 (m, 8H), 5.66 (q, J = 7.0 Hz, 1H), 5.64 
(s, 1H), 3.36-3.44 (m, 2h) 3.22 (d, J = 9.0 Hz, 1H), 2.68 (d, J = 9.0 Hz, 1H), 2.02 (br s, 
1H), 1.85 (d, J = 7.5 Hz, 3H),  0.87 (s, 3H), 0.85 (s, 3H). 1H NMR (500 MHz, CDCl3, 
minor) d 7.84-7.85 (m, 1H), 7.27-7.58 (m, 8H), 6.00 (s, 1H), 5.36 (q, J = 7.0 Hz, 1H), 3.15-
3.17 (m, 2H), 2.59 (d, J = 9.0 Hz, 1H), 2.54 (d, J = 9.0 Hz, 1H), 1.89 (d, J = 7.5 Hz, 3H), 
1.76 (br s, 1H), 0.70 (s, 3H), 0.63 (s, 3H). 13C NMR (125 MHz, CDCl3) d 167.8, 141.7, 
141.1, 140.7, 140.3, 133.1, 132.7, 132.2, 132.1, 130.0, 129.9, 128.7, 128.5, 127.8, 127.7, 
127.5, 123.7, 123.5, 123.2, 123.0, 85.7 (major), 85.5 (minor), 70.8, 70.5, 69.8, 50.8, 50.7, 
35.9, 35.6, 21.8, 21.6, 18.0, 17.8. HRMS (FTMS + p ESI) m/z [M + Na]+; calculated for 


















Pale yellow solid ( 138mg, 78%); mp 85-87 °C; Rf = 0.25 (hexane/ethyl acetate, 2:1);  IR 
3056, 3035, 2927, 2854, 1696 cm -1 A mixture of two inseparable diastereomers (dr = 3:2) 
1H NMR (400 MHz, CDCl3, major) d 8.43 (s, 1H), 7.95-7.96 (m, 3H), 7.86-7.89 (m, 1H), 
7.26-7.72 (m, 12H), 6.98 (d, J = 7.2 Hz, 1H), 5.86 (s, 1H), 5.80 (q, J = 7.2 Hz, 1H), 5.34 
(d, J = 12.0 Hz, 1H), 5.12 (d, J = 12.0 Hz, 1H), 1.90 (d, J = 7.6 Hz, 3H). 1H NMR (400 
MHz, CDCl3, minor) d 8.39 (s, 1H), 7.95-7.96 (m, 3H), 7.86-7.89 (m, 1H), 7.26-7.72 (m, 
12H), 7.18 (d, J = 7.2 Hz, 1H), 6.10 (s, 1H), 5.40 (q, J = 7.2 Hz, 1H), 4.85 (q, J = 7.6 Hz, 
2H), 2.04 (d, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3) d 168.4, 168.3, 142.0, 141.4, 
140.9, 140.7, 133.2, 132.5, 132.0, 131.9, 131.4, 130.5, 130.4, 129.9, 129.8, 129.0, 128.9, 
128.8, 128.6, 128.5, 128.3, 127.7, 127.6, 126.5, 126.1, 124.9, 124.9, 124.2, 124.0, 123.8, 
123.7, 123.6, 86.3 (major), 86.0 (minor), 58.0, 57.1, 51.6, 51.0, 18.5, 18.3. HRMS (FTMS 
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Ac2O Acetic anhydride 
AcOH Acetic acid 
ACE Angiotensin Converting Enzyme 
BPCC 2,2'-bipyridinium chlorochromate 
Br2 Molecular Bromine 
BRD4 Bromodomain-containing 
CHCl3 Chloroform 
Cs2CO3 Cesium Carbonate 
CSA Camphorsulfonic Acid 
Cu Copper 
Cu(OAc)2 Copper Acetate 
CuSO4 Copper sulfate 
DAST Diethylaminosulfur trifluoride 
DCM Dichloromethane 
DMSO Dimethylsulfoxide 
ENL Erythema Nodosum Leprosum 
ESI Electrospray Ionization 
Et Ethyl 
FT-IR Fourier Transform Infrared Spectroscopy 
G Grams 
H Hours 
HRMS High Resolution Mass Spectrometry 
Hz Hertz 
IBX 2-Iodobenzoic acid 
IFN-γ Interferon γ 
IKZF Ikaros family zinc finger 
IMiDs Immunomodulatory Drugs 
KBr Potassium Bromide 
LiHMDS Lithium Hexamethyl disilazide 
LRMS Low Resolution Mass Spectrometry 





mL  Milliliters 
mmol Millimole 
Mp Melting Point 
N2 Nitrogen gas 
270 
N2H4 Hydrazine 
Na2CO3 Sodium Carbonate 
NaH Sodium Hydride 
NaN3 Sodium azide 
NMR Nuclear Magnetic Resonance 
Phth Phthaloyl 
PMB p-Methoxybenzyl 
PMB-Cl 4-Methoxybenzyl Chloride 
PROTAC Proteolysis-targeting chimera 
rt Room temperature 
SeO2 Selenium Oxide 
TBAF Tetra-n-butylammonium Fluoride 
tBu tert-Butyl 
THF Tetrahydrofuran 
TLC Thin-Layer Chromatography 
TNF-⍺ Tumor Necrosis Factor ⍺ 
TOF Time of Flight 
TsOH p-Toluenesulfonic Acid 
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